<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11598775</article-id><article-id pub-id-type="pmcid-ver">PMC11598775.1</article-id><article-id pub-id-type="pmcaid">11598775</article-id><article-id pub-id-type="pmcaiid">11598775</article-id><article-id pub-id-type="pmid">39591123</article-id><article-id pub-id-type="doi">10.3390/vaccines12111220</article-id><article-id pub-id-type="publisher-id">vaccines-12-01220</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1173-335X</contrib-id><name name-style="western"><surname>Muthukutty</surname><given-names initials="P">Palaniyandi</given-names></name><xref rid="fn1-vaccines-12-01220" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9063-3730</contrib-id><name name-style="western"><surname>MacDonald</surname><given-names initials="J">Jaime</given-names></name><xref rid="fn1-vaccines-12-01220" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8875-9289</contrib-id><name name-style="western"><surname>Yoo</surname><given-names initials="SY">So Young</given-names></name><xref rid="c1-vaccines-12-01220" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Tripp</surname><given-names initials="RA">Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01220">Institute of Nanobio Convergence, Pusan National University, Busan 46241, Republic of Korea; <email>pmkpalani@gmail.com</email> (P.M.); <email>jaimemac.bgv@gmail.com</email> (J.M.)</aff><author-notes><corresp id="c1-vaccines-12-01220"><label>*</label>Correspondence: <email>yoosy2@gmail.com</email> or <email>yoosy@pusan.ac.kr</email></corresp><fn id="fn1-vaccines-12-01220"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2024</year></pub-date><volume>12</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">475872</issue-id><elocation-id>1220</elocation-id><history><date date-type="received"><day>24</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>10</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-29 01:25:35.527"><day>29</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-12-01220.pdf"/><abstract><p>Emerging viral diseases, including seasonal illnesses and pandemics, pose significant global public health risks. Respiratory viruses, particularly coronaviruses and influenza viruses, are associated with high morbidity and mortality, imposing substantial socioeconomic burdens. This review focuses on the current landscape of respiratory viruses, particularly influenza and SARS-CoV-2, and their antiviral treatments. It also discusses the potential for pandemics and the development of new antiviral vaccines and therapies, drawing lessons from past outbreaks to inform future strategies for managing viral threats.</p></abstract><kwd-group><kwd>respiratory viruses</kwd><kwd>pandemic</kwd><kwd>epidemic</kwd><kwd>coronavirus</kwd><kwd>influenza virus</kwd><kwd>antivirals</kwd></kwd-group><funding-group><award-group><funding-source>Korea Technology and Information Promotion Agency for SMEs</funding-source><award-id>S3302176</award-id></award-group><award-group><funding-source>Korea Health Industry Development Institute (KHIDI)</funding-source><funding-source>Ministry of Health and Welfare, Republic of Korea</funding-source><award-id>HI22C0607</award-id></award-group><award-group><funding-source>SUNJE Co., Ltd. (SUNJAE-PNU Industry-Academic Cooperation)</funding-source></award-group><funding-statement>This research was supported by grants from the Korea Health Technology R&amp;D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI22C0607), and the Industry-Academic Collabo R&amp;D Program (S3302176), funded by the Korea Technology and Information Promotion Agency for SMEs. This study was also supported by SUNJE Co., Ltd. (SUNJAE-PNU Industry-Academic Cooperation).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-vaccines-12-01220"><title>1. Respiratory Viruses: An Overview</title><p>Respiratory infections are a major global health concern due to their widespread prevalence, ease of transmission, and high morbidity and mortality, particularly in young children, the elderly, and immunocompromised individuals [<xref rid="B1-vaccines-12-01220" ref-type="bibr">1</xref>]. While often self-limiting and confined to the upper airways, these infections can cause severe lower respiratory tract diseases such as bronchiolitis and pneumonia in vulnerable populations: common cold (caused by rhinovirus, coronavirus, respiratory syncytial virus (RSV), and parainfluenza virus), bronchiolitis (caused by RSV), and pneumonia (caused by coronaviruses, RSV, and most influenza viruses) [<xref rid="B2-vaccines-12-01220" ref-type="bibr">2</xref>]. Viral transmission occurs through inhalation of airborne particles or contact with contaminated surfaces, leading to infection of respiratory mucosal cells. Seasonal and environmental factors, as well as zoonotic events, influence the incidence and severity of respiratory virus epidemics [<xref rid="B3-vaccines-12-01220" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01220" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-12-01220" ref-type="bibr">5</xref>]. Understanding the transmission dynamics and host-pathogen interactions is crucial for developing effective prevention and treatment strategies.</p><p>Epidemiological studies indicate that seasonal and environmental factors, such as host susceptibility to temperature, humidity, host behavior, and immune tolerance, can influence respiratory virus epidemics [<xref rid="B6-vaccines-12-01220" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01220" ref-type="bibr">7</xref>]. Endemic strains of respiratory viruses (RVs), such as influenza and coronavirus, cause recurring seasonal infections; however, climatic changes and evolving animal trade and consumption can lead to zoonotic events, such as the highly pathogenic avian influenza A virus outbreaks and the recent SARS-CoV-2 pandemic (COVID-19) [<xref rid="B8-vaccines-12-01220" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-12-01220" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-12-01220" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01220" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01220" ref-type="bibr">12</xref>]. The interaction type and duration of contact with an infected animal determine zoonotic transmission efficiency, which can be spontaneous and sporadic. Human infection is determined by the availability of susceptible host receptors, which act as initial barriers against the highly evolved, multilayered human immune system [<xref rid="B13-vaccines-12-01220" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01220" ref-type="bibr">14</xref>]. When animal viruses that do not typically infect humans encounter the human immune system, they frequently trigger unbalanced activation of early innate immune response pathways [<xref rid="B15-vaccines-12-01220" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01220" ref-type="bibr">16</xref>]. Cell types expressing receptors that define the tissue tropism of the virus play a vital role in determining the severity and dynamics of viral infections [<xref rid="B17-vaccines-12-01220" ref-type="bibr">17</xref>]. Infections caused by highly pathogenic viruses can also result in systemic viral replication, secondary bacterial infections, and multi-organ damage [<xref rid="B18-vaccines-12-01220" ref-type="bibr">18</xref>].</p><p>Four past pandemics have been caused by RNA-based RVs, primarily influenza virus strains [<xref rid="B19-vaccines-12-01220" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01220" ref-type="bibr">20</xref>]. The 2009 H1N1 influenza virus pandemic and the 2019 coronavirus (COVID-19) pandemic are the most recent examples (<xref rid="vaccines-12-01220-t001" ref-type="table">Table 1</xref>). Given the antigenic mutations observed in both RVs, future pandemics seem inevitable [<xref rid="B21-vaccines-12-01220" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-12-01220" ref-type="bibr">22</xref>]. To mitigate these threats, a thorough understanding of virology, genomic mutations, epidemiological characteristics, and immune evasion mechanisms is essential, and prevention strategies such as antiviral therapies must be developed to efficiently control RV outbreaks [<xref rid="B23-vaccines-12-01220" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01220" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01220" ref-type="bibr">25</xref>].</p><p>In this review, we comprehensively discuss current and potential future antiviral strategies for neutralizing emerging RVs, with particular focus on influenza and coronavirus.</p></sec><sec id="sec2-vaccines-12-01220"><title>2. Virology of Respiratory Viruses: Influenza and Coronavirus</title><p>Influenza viruses, part of the Orthomyxoviridae family, are classified into four types, namely, A, B, C, and D. Influenza A is responsible for the most severe illness and is known for causing seasonal epidemics and pandemics [<xref rid="B30-vaccines-12-01220" ref-type="bibr">30</xref>]. Since 1918, influenza A viruses have caused four pandemics, including the 2009 H1N1 outbreak. These viruses affect all age groups, with higher disease severity in infants, the elderly, and individuals with chronic health conditions [<xref rid="B31-vaccines-12-01220" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-12-01220" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-12-01220" ref-type="bibr">33</xref>]. Influenza viruses are enveloped, single-stranded, negative-sense RNA viruses with eight segments of negative-sense RNA that encode various proteins, including hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), and matrix protein (M). The HA and NA proteins are crucial for determining host species tropism and are classified into subtypes based on the number of HA and NA variants. The HA (H1, H2, and H3) and NA (N1 and N2) subtypes are most frequently responsible for human infection and pandemics [<xref rid="B34-vaccines-12-01220" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-12-01220" ref-type="bibr">35</xref>]. Influenza A virus is characterized by their high potential for antigenic shift and drift. Antigenic shift refers to the reassortment of viral RNA segments, while antigenic drift involves the gradual accumulation of point mutations due to the virus&#8217;s poor proofreading ability during replication [<xref rid="B36-vaccines-12-01220" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-12-01220" ref-type="bibr">37</xref>]. Both processes contribute to the emergence of novel strains capable of escaping pre-existing immunity and causing future outbreaks.</p><p>Coronaviruses, belonging to the Coronaviridae family, are enveloped viruses with a positive-sense single-stranded RNA (ssRNA) genome, ranging in size from 26 to 32 kb, among the largest of all RNA viruses [<xref rid="B38-vaccines-12-01220" ref-type="bibr">38</xref>]. They derive their name from the crown-like spikes (glycoproteins) that protrude from their surface. These glycoproteins bind to specific receptors in humans and animals, facilitating cross-species transmission. Currently, seven coronaviruses are known to infect humans, causing symptoms ranging from the common cold to severe respiratory illnesses. Major recent epidemics caused by coronavirus include the 2003 Severe Acute Respiratory Syndrome (SARS-CoV), the 2013 Middle Eastern Respiratory Syndrome (MERS-CoV), and the 2019 SARS-CoV-2 (COVID-19) [<xref rid="B39-vaccines-12-01220" ref-type="bibr">39</xref>].</p><p>SARS-CoV-2 shares approximately 80% sequence similarity with SARS-CoV and about 50% with MERS-CoV [<xref rid="B40-vaccines-12-01220" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-01220" ref-type="bibr">41</xref>]. It is a positive-sense RNA virus with 14 open reading frames encoding 27 proteins upon infection, including the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins [<xref rid="B42-vaccines-12-01220" ref-type="bibr">42</xref>]. The spike protein, particularly its receptor-binding domain (RBD), interacts with angiotensin-converting enzyme 2 (ACE2) receptors on human cells, enabling the virus to enter host cells and initiate infection. SARS-CoV-2 also employs co-receptors such as transmembrane serine protease 2 (TMPRSS2) to facilitate viral entry into the host [<xref rid="B43-vaccines-12-01220" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-12-01220" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-12-01220" ref-type="bibr">45</xref>]. Viral ligand-cellular membrane receptor specificity determines the tropism of viruses to specific cells or tissues, which influences pathogenic symptoms. For cell infection to occur, a sufficient density of membrane receptors must bind to ligands on the virion surface [<xref rid="B46-vaccines-12-01220" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-12-01220" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-12-01220" ref-type="bibr">48</xref>].</p><p>Coronaviruses that cause severe respiratory diseases, such as SARS, contain spike proteins that interact with receptors like ACE2 on host cells. SARS-CoV-2 primarily targets lung and bronchial epithelial cells by binding to ACE2 receptors. The spike (S) glycoprotein consists of two subunits, S1 and S2, with the S1 subunit containing the receptor-binding domain (RBD). Furin, a proteinase, facilitates viral entry by cleaving the S1/S2 site of spike protein and mediates membrane fusion [<xref rid="B49-vaccines-12-01220" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-12-01220" ref-type="bibr">50</xref>]. Other proteinases that facilitate virus entry, such as alanyl-aminopeptidase (ANPEP), glutamyl aminopeptidase (ENPEP), and transmembrane serine protease 2 (TMPRSS2), may also aid in the infection of lung cells [<xref rid="B50-vaccines-12-01220" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-01220" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-12-01220" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01220" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-12-01220" ref-type="bibr">54</xref>].</p><p>As SARS-CoV-2 enters the respiratory system, it damages the tracheal mucosa. Symptoms include fatigue, fever, and coughing [<xref rid="B55-vaccines-12-01220" ref-type="bibr">55</xref>]. Severe infections lead to inflammation that damages the surrounding connective tissues, severely affecting the bronchioles and alveoli. The accumulation of inflammatory exudate in the alveoli hinders the exchange of oxygen and carbon dioxide, causing respiratory distress. This leads to further systemic damage, affecting the liver, kidney, neurological system, and other organs due to the lack of oxygen. Complications are exacerbated by a cytokine storm, which worsens the severity of infection [<xref rid="B2-vaccines-12-01220" ref-type="bibr">2</xref>,<xref rid="B56-vaccines-12-01220" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01220" ref-type="bibr">57</xref>].</p></sec><sec id="sec3-vaccines-12-01220"><title>3. Immune Response Against Respiratory Viruses: Influenza and Coronavirus</title><p>To develop an effective treatment regimen for viral respiratory infections, it is crucial to first understand the dynamics of systemic inflammatory responses. Individuals infected with RVs may be contagious one to two days before exhibiting symptoms and can remain infectious for several days after symptoms appear [<xref rid="B58-vaccines-12-01220" ref-type="bibr">58</xref>]. Immunocompromised individuals may remain contagious for longer than the typical infectious period [<xref rid="B59-vaccines-12-01220" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01220" ref-type="bibr">60</xref>].</p><p>Most RVs, including influenza and coronaviruses, trigger an immune response in the epithelial cells of the respiratory tract once infection occurs. In addition to epithelial cells, immune cells, such as alveolar macrophages and dendritic cells (DCs), play a vital role in detecting invading viruses through pattern recognition receptors (PRRs) [<xref rid="B61-vaccines-12-01220" ref-type="bibr">61</xref>]. These receptors recognize pathogen-associated molecular patterns (PAMPSs), initiating a cascade of signals that stimulate the production of various cytokines and chemokines. These inflammatory mediators alert innate immune cells, triggering a series of antiviral defense mechanisms. The innate immune recognition of viral infections activates gene expression that recruits inflammatory cells to the site of infection [<xref rid="B62-vaccines-12-01220" ref-type="bibr">62</xref>]. Early cytokines involved in the response are primarily members of the type I interferon family, including IFN-&#945; and IFN-&#946; [<xref rid="B63-vaccines-12-01220" ref-type="bibr">63</xref>]. Additionally, epithelial cells and alveolar macrophages produce chemokines, which recruit monocytes and T cells to the infection sites [<xref rid="B64-vaccines-12-01220" ref-type="bibr">64</xref>]. The coordinated expression of cytokines and chemokines leads to DC maturation, enabling antigen presentation to T cells in the draining lymph nodes. In summary, a localized inflammatory response, recruitment of innate immune cells, and cytokine-mediated signals influence DC maturation and migration to lymph nodes, where the adaptive immune response begins, playing a vital role in antiviral defense [<xref rid="B65-vaccines-12-01220" ref-type="bibr">65</xref>].</p><p>Following the activation of the innate immune system, DCs migrate to lymph nodes, where they stimulate CD4+ and CD8+ T cell activation via major histocompatibility complex (MHC) interactions [<xref rid="B66-vaccines-12-01220" ref-type="bibr">66</xref>]. The presence of na&#239;ve T cells specific to the antigen, along with co-stimulatory signals, results in the priming of T cells [<xref rid="B67-vaccines-12-01220" ref-type="bibr">67</xref>]. DC activation and maturation trigger the accumulation of virus-specific effector T-cells. T-cell receptor affinity, avidity, and co-stimulation from the local inflammatory environment influence the generation of differentiated effector T-cells, which then exit the lymph nodes and migrate to the lungs [<xref rid="B68-vaccines-12-01220" ref-type="bibr">68</xref>]. During the adaptive phase of the immune response, the expression of chemokines, chemokine receptors, and molecules associated with T cell trafficking increases [<xref rid="B69-vaccines-12-01220" ref-type="bibr">69</xref>]. Effector T cells in circulation recognize chemokines in infected areas, leading to changes in integrin affinity on blood vessel walls, facilitating extravasation into the virus-infected regions. As more effector T cells accumulate in the lungs, the viral load decreases, and infected cells are lysed [<xref rid="B70-vaccines-12-01220" ref-type="bibr">70</xref>]. A schematic illustration of RV infection through the respiratory tract and the subsequent inflammatory response that triggers a severe &#8216;cytokine storm&#8217;, elevating the disease&#8217;s severity, is shown in <xref rid="vaccines-12-01220-f001" ref-type="fig">Figure 1</xref>.</p></sec><sec id="sec4-vaccines-12-01220"><title>4. Epidemiology and Transmission Dynamics: Influenza and Coronavirus</title><p>Respiratory droplets, aerosol transmission, and direct contact with contaminated surfaces are key human-to-human transmission pathways for both coronaviruses and influenza A viruses [<xref rid="B74-vaccines-12-01220" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-12-01220" ref-type="bibr">75</xref>]. The risk of contracting these viruses is significantly higher when individuals are in close proximity to an infected person who is coughing, sneezing, or speaking [<xref rid="B76-vaccines-12-01220" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-12-01220" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-12-01220" ref-type="bibr">78</xref>]. Moreover, studies have detected viral particles in the feces of individuals infected with COVID-19 or influenza A, indicating potential for fecal&#8211;oral transmission [<xref rid="B79-vaccines-12-01220" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-12-01220" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-12-01220" ref-type="bibr">81</xref>]. Body secretions and fluids from confirmed cases are generally regarded as contagious [<xref rid="B82-vaccines-12-01220" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-12-01220" ref-type="bibr">83</xref>]. Notably, influenza A has affected 9.3% of children aged 0 to 17, 8.8% of adults aged 18 to 64, and 3.9% of adults aged 65 and older [<xref rid="B84-vaccines-12-01220" ref-type="bibr">84</xref>]. In contrast, elderly individuals and those with underlying health conditions are the most vulnerable groups for COVID-19, with a higher probability of developing severe disease [<xref rid="B85-vaccines-12-01220" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-12-01220" ref-type="bibr">86</xref>].</p><p>Some reports indicate that individuals infected with influenza A typically develop symptoms with one week of exposure and can be contagious one day prior to symptom appearance [<xref rid="B87-vaccines-12-01220" ref-type="bibr">87</xref>]. Notably, 80% of infected individuals may still be contagious up to five days after symptom resolution [<xref rid="B88-vaccines-12-01220" ref-type="bibr">88</xref>]. In the case of COVID-19, early studies revealed a median incubation period of approximately five days, with 97.5% of cases presenting symptoms within 11.5 days [<xref rid="B89-vaccines-12-01220" ref-type="bibr">89</xref>]. In rare cases, the incubation period has extended to as long as 16 days [<xref rid="B90-vaccines-12-01220" ref-type="bibr">90</xref>]. During the 1918 influenza A pandemic, an estimated one-third of the global population was infected, with approximately 50&#8211;100 million deaths attributed to the virus [<xref rid="B91-vaccines-12-01220" ref-type="bibr">91</xref>]. As of 2023, the World Health Organization reported that around 702 million people have been infected with COVID-19, resulting in 6.9 million deaths [<xref rid="B92-vaccines-12-01220" ref-type="bibr">92</xref>]. Currently, global vaccination efforts are considered the most effective strategy for controlling the spread of COVID-19 [<xref rid="B93-vaccines-12-01220" ref-type="bibr">93</xref>].</p></sec><sec id="sec5-vaccines-12-01220"><title>5. Antiviral Therapies for Respiratory Viruses: Influenza and Coronavirus</title><p>Antiviral agents are therapies designed to directly target a virus or its components to suppress its activity. This broad category includes a wide variety of therapies [<xref rid="B94-vaccines-12-01220" ref-type="bibr">94</xref>]. Antivirals typically interfere with viral entry or replication by disrupting the virus&#8217;s internal machinery (<xref rid="vaccines-12-01220-f002" ref-type="fig">Figure 2</xref>). Common targets include viral RNA-dependent RNA polymerase (RdRp), proteases, and spike proteins. Each antiviral works through a specific mechanism to inhibit viral replication, either by disrupting the function of RdRp or reducing the efficiency of viral RNA replication. Targeting viral proteases, for example, interferes with the post-translational processing of viral progeny, which is essential for producing fully functional viruses. In addition, antiviral agents that target spike proteins usually bind to critical regions involved in viral attachment and entry into host cells. This process, known as viral neutralization, prevents the virus from entering and infecting cells, a topic that will be discussed in more detail in a separate section.</p><sec id="sec5dot1-vaccines-12-01220"><title>5.1. Antiviral Drug Options for Influenza Virus</title><p>Several antiviral drugs against the influenza virus have been developed and are approved by various regulatory authorities worldwide. These drugs target key stages of the viral infection and replication process, effectively inhibiting viral spread [<xref rid="B97-vaccines-12-01220" ref-type="bibr">97</xref>]. Some of the antivirals approved by the world drug authorities are listed in <xref rid="vaccines-12-01220-t002" ref-type="table">Table 2</xref>.</p><p>Baloxavir is an antiviral that prevents influenza infection by blocking the conversion of viral RNA to mRNA. This inhibition occurs when baloxavir captures the 5&#8217; cap of pre-mRNA by binding and inactivating the polymerase enzyme, thereby halting viral replication.</p><p>Zanamivir (trade name Relenza) was the first neuraminidase inhibitor (NAI) approved by the FDA in 1999. Administered via intranasal or oral inhalation, zanamivir can reduce symptoms and lessen the need for antibiotics when taken at the onset of the infection [<xref rid="B98-vaccines-12-01220" ref-type="bibr">98</xref>]. Of note, zanamivir has poor oral bioavailability, making inhalation a more effective method for inhibiting viral replication [<xref rid="B99-vaccines-12-01220" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-12-01220" ref-type="bibr">100</xref>].</p><p>Oseltamivir (trade name Tamiflu) is another NAI that prevents viral particles from binding to host cells, leading to functional inactivation of the virus and subsequent endocytosis by host cells [<xref rid="B101-vaccines-12-01220" ref-type="bibr">101</xref>].</p><p>Peramivir (trade name Rapivab) is a cyclopentane sialic acid analog that inhibits both influenza A and B viruses by targeting NA. This antiviral is notable for being the first intravenous NAI approved for use in critically ill patients. Peramivir binds more effectively to NA than other NAIs. It was approved for influenza treatment in Japan and Korea in 2010 and by the FDA in the United States in 2014. Several studies have demonstrated the safety and efficacy of peramivir [<xref rid="B102-vaccines-12-01220" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-12-01220" ref-type="bibr">103</xref>].</p><table-wrap position="anchor" id="vaccines-12-01220-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of approved antiviral treatments for influenza virus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antiviral Agents</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Category</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Favipiravir (Avigan<sup>&#174;</sup>, Toyama Chemical, Tokyo, Japan)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B, SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA-dependent RNA polymerase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Investigational for COVID-19 and influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-vaccines-12-01220" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oseltamivir (Tamiflu<sup>&#174;</sup>, Roche, Basel, Switzerland)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor (prevents viral release)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment and prophylaxis of influenza A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-vaccines-12-01220" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Zanamivir (Relenza<sup>&#174;</sup>, GSK, Middlesex, UK)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhalation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus budding inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of influenza A and B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-vaccines-12-01220" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peramivir (Rapivab<sup>&#174;</sup>, BioCryst Pharmaceuticals, Durham, NC, USA)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus budding inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute, uncomplicated influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-vaccines-12-01220" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Baloxavir marboxil (Xofluza, Shionogi, Osaka, Japan)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enzyme inhibitor, targeting the influenza virus&#8217; cap-dependent endonuclease activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cap-dependent endonuclease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA polymerase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For individuals who are twelve years of age or older that have presented symptoms of this infection for no more than 48 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-vaccines-12-01220" ref-type="bibr">107</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>CT: clinical trial; FDA: Food and Drug Administration.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec5dot2-vaccines-12-01220"><title>5.2. Antiviral Drug Options for Coronavirus (SARS-CoV-2)</title><p>Based on previous experience with coronaviruses, such as SARS and MERS, antiviral medications have been employed since the early stages of the COVID-19 pandemic to disrupt the viral replicative cycle in patients. Current antiviral therapies target either viral proteins or host proteins that are essential for viral propagation.</p><p>Antivirals are most effective when administered during the early stages of the disease. For optimal outcomes, these treatments should be initiated within five days of symptom onset [<xref rid="B108-vaccines-12-01220" ref-type="bibr">108</xref>]. Delayed administration often results in reduced efficacy. Currently, several antiviral therapies have received emergency-use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-19 treatment, including remdesivir, molnupiravir, and paxlovid (a combination of nirmatrelvir and ritonavir). Some of the approved antiviral drugs for SARS-CoV-2 are listed in <xref rid="vaccines-12-01220-t003" ref-type="table">Table 3</xref>.</p><sec id="sec5dot2dot1-vaccines-12-01220"><title>5.2.1. Viral RNA-Dependent RNA Polymerase (RdRp) Targeting Drugs</title><list list-type="simple"><list-item><label>(a)</label><p>Remdesivir</p></list-item></list><p>Remdesivir (Veklury<sup>&#174;</sup>, Gilead Sciences, Foster, CA, USA) is an antiviral therapy initially developed to treat Ebolavirus and Marburg virus. It functions as a polymerase inhibitor, targeting the viral RdRp, an enzyme essential for viral RNA transcription. Since RdRp is highly conserved across coronaviruses, inhibiting this protein is a promising strategy for impeding viral replication. Remdesivir is a nucleoside analog of adenosine, which once metabolized into its active triphosphate form competes with ATP for binding with RdRp. This competition results in the incorporation of remdesivir into the nascent viral RNA strand. After these three nucleotides are added, RNA synthesis is prematurely terminated. The addition of these three nucleotides may also protect against viral exonucleases, further stalling the replication process [<xref rid="B109-vaccines-12-01220" ref-type="bibr">109</xref>]. As such, remdesivir acts as a chain-terminating nucleoside analog that halts RdRp activity [<xref rid="B96-vaccines-12-01220" ref-type="bibr">96</xref>].</p><p>While remdesivir is the most effective when administered early in the infection, studies have shown that it can also produce positive outcomes in later stages of severe COVID-19 infection. It is currently the only antiviral fully approved by the FDA for treating COVID-19. In contrast, most other antiviral treatments have only received EUA. The FDA has approved remdesivir for use in both hospitalized and non-hospitalized adults, as well as specific pediatric patients, particularly those at high risk of developing severe illness. Remdesivir has also demonstrated efficacy against emerging variants. Although meta-analyses have shown mixed results regarding its effectiveness, with some studies suggesting a protective benefit and others showing limited impact, remdesivir has generally improved clinical outcomes in hospitalized patients, though it has not significantly reduced mortality rates [<xref rid="B110-vaccines-12-01220" ref-type="bibr">110</xref>].</p><list list-type="simple"><list-item><label>(b)</label><p>Molnupiravir</p></list-item></list><p>Molnupiravir (trade name Lagevrio, Merck, Kenilworth, NJ, USA) is an RdRp inhibitor that limits viral replication and has shown activity against coronaviruses, including SARS-CoV-2. Unlike remdesivir, which causes stalling of RdRp, molnupiravir induces RNA mutagenesis, resulting in an increase in mutation frequency that prevents the formation of viable virions. As a nucleoside analog, molnupiravir is incorporated into the viral RNA during replication, leading to the accumulation of mutations that ultimately inhibit viral propagation [<xref rid="B111-vaccines-12-01220" ref-type="bibr">111</xref>]. A meta-analysis of clinical trials demonstrated that approximately 95% of patients showed clinical improvement by day 5 of treatment with molnupiravir [<xref rid="B112-vaccines-12-01220" ref-type="bibr">112</xref>]. In December 2021, the FDA granted EUA of molnupiravir to adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease resulting in hospitalization or death and for whom no other treatment options are available or appropriate. For maximum efficacy, treatment with molnupiravir should be started immediately after COVID-19 diagnosis and within five days of symptom onset. Currently, molnupiravir is recommended for patients with mild COVID-19 who are at a high risk of hospitalization [<xref rid="B113-vaccines-12-01220" ref-type="bibr">113</xref>,<xref rid="B114-vaccines-12-01220" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-12-01220" ref-type="bibr">115</xref>].</p></sec><sec id="sec5dot2dot2-vaccines-12-01220"><title>5.2.2. Other Antiviral Drugs</title><list list-type="simple"><list-item><label>(a)</label><p>Favipiravir</p></list-item></list><p>Favipiravir is a modified pyrazine analog originally approved for the treatment of Ebola and influenza viruses. Like remdesivir, favipiravir acts as a nucleoside analog that inhibits RdRp by being incorporated into nascent viral RNA strands, leading to chain termination. The incorporation also results in a high mutation rate that reduces the production of viable virions [<xref rid="B116-vaccines-12-01220" ref-type="bibr">116</xref>]. While favipiravir can shorten the duration of viral clearance, it has limitations due to the exonuclease activity of viral RdRp, which allows for proofreading and mutation repair. Favipiravir is not recommended in the latest international treatment guidelines for COVID-19 [<xref rid="B104-vaccines-12-01220" ref-type="bibr">104</xref>,<xref rid="B117-vaccines-12-01220" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-12-01220" ref-type="bibr">118</xref>].</p><list list-type="simple"><list-item><label>(b)</label><p>Ribavirin</p></list-item></list><p>Ribavirin is a synthetic nucleoside analog of ribofuranose, primarily used for RNA viruses, including the hepatitis C virus. It alters the viral genome by integrating into the viral RNA, preventing proper replicating. Ribavirin binds to viral RdRp with an affinity comparable to native nucleotides. However, it is not used to treat COVID-19 due to its unfavorable side effects and low efficacy [<xref rid="B119-vaccines-12-01220" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-12-01220" ref-type="bibr">120</xref>].</p><p>Protease enzymes are essential for viral protein maturation as they cleave translated viral polypeptides into functional proteins, making them potential targets for viral therapy. Studies have explored the potential use of protease inhibitors for COVID-19, focusing on the SARS-CoV-2 major protease (M-pro or 3CL-pro), which is essential for viral replication. Molecules that bind M-pro can disrupt its catalytic activity, reducing viral replication [<xref rid="B121-vaccines-12-01220" ref-type="bibr">121</xref>].</p><list list-type="simple"><list-item><label>(c)</label><p>Lopinavir/Ritonavir</p></list-item></list><p>Lopinavir is a protease inhibitor initially developed for HIV-1 treatment and is currently used in combination with ritonavir for HIV-AIDS. The combination of lopinavir and ritonavir was also tested for COVID-19. Although this combination alone has proven ineffective in treating COVID-19 patients, it may provide benefits when combined with other therapies [<xref rid="B122-vaccines-12-01220" ref-type="bibr">122</xref>]. Lopinavir specifically inhibits SARS-CoV-2&#8217;s M-pro, avoiding off-target effects. Ritonavir boosts the effectiveness of lopinavir by inhibiting cytochrome P450 (CYP3A4), which extends the half-life of lopinavir and enhances its suppression of SARS-CoV-2 replication. However, evidence supporting the efficacy of lopinavir/ritonavir in COVID-19 treatment is insufficient, and current WHO guidelines do not recommend its use [<xref rid="B121-vaccines-12-01220" ref-type="bibr">121</xref>,<xref rid="B123-vaccines-12-01220" ref-type="bibr">123</xref>].</p><list list-type="simple"><list-item><label>(d)</label><p>Nirmatrelvir/Ritonavir (Paxlovid)</p></list-item></list><p>Nirmatrelvir is a potent M-pro inhibitor, originally developed to combat SARS-CoV-1. The FDA approved the use of this combination (under the trade name Paxlovid, Pfizer, New York, NY) for treating COVID-19 [<xref rid="B124-vaccines-12-01220" ref-type="bibr">124</xref>]. Studies have shown that nirmatelvir/ritonavir reduces hospitalization and mortality rates in COVID-19 patients, although further research is needed to confirm its efficacy. Currently, the WHO guidelines recommend nirmatrelvir/ritonavir for COVID-19 treatment, as it may be more effective than other options in preventing severe disease and hospitalization [<xref rid="B125-vaccines-12-01220" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-12-01220" ref-type="bibr">126</xref>].</p></sec><sec id="sec5dot2dot3-vaccines-12-01220"><title>5.2.3. Convalescent Plasma</title><p>Convalescent plasma therapy was introduced in the 1890s by Emil Von Behring and Shibasaburo Kitasato as a treatment for infectious disease [<xref rid="B127-vaccines-12-01220" ref-type="bibr">127</xref>]. This approach leverages the role of antibodies in neutralizing antigens, with the passive administration of pathogen-specific polyclonal or monoclonal antibodies (mAbs) preventing viral entry into host cells, thus inhibiting infection. Due to the initial lack of approved and effective therapies for COVID-19, convalescent plasma was one of the first treatments explored during the early stages of the pandemic. Historical use of convalescent plasma (obtained from individuals who recovered from viral infections) dates back to the 1918 flu pandemic [<xref rid="B127-vaccines-12-01220" ref-type="bibr">127</xref>].</p><p>Shen et al. reported the use of convalescent plasma transfusion in five critically ill patients with COVID-19, resulting in clinical improvements and viral neutralization [<xref rid="B128-vaccines-12-01220" ref-type="bibr">128</xref>]. In August 2020, the U.S. FDA approved and granted EUA for the use of convalescent plasma to treat hospitalized patients with COVID-19 [<xref rid="B129-vaccines-12-01220" ref-type="bibr">129</xref>]. Most clinical studies investigating this therapy have found that convalescent plasma is primarily associated with only minor transfusion-related adverse events; this result is despite conflicting data on its effectiveness in patients with COVID-19 in terms of the time of administration during the course of the disease, number of infusions required, and optimal titers. Several clinical studies have reported no significant improvement in hospitalized patients with COVID-19. However, patients can benefit from early infusion of high-titer convalescent plasma [<xref rid="B130-vaccines-12-01220" ref-type="bibr">130</xref>,<xref rid="B131-vaccines-12-01220" ref-type="bibr">131</xref>]. Ongoing clinical trials continue to explore the potential effectiveness of convalescent plasma transfusion as a COVID-19 therapy [<xref rid="B132-vaccines-12-01220" ref-type="bibr">132</xref>,<xref rid="B133-vaccines-12-01220" ref-type="bibr">133</xref>].</p></sec><sec id="sec5dot2dot4-vaccines-12-01220"><title>5.2.4. Monoclonal Antibodies</title><p>mAbs are merged as effective therapeutic agents for specifically targeting SARS-CoV-2, as they help restore immunological balance by inducing a rapid, passive immune response. This response aids in the destruction of infected cells and reduces the viral load [<xref rid="B134-vaccines-12-01220" ref-type="bibr">134</xref>]. Many mAbs have received emergency authorization for the treatment of individuals with mild-to-moderate COVID-19, showing significant efficacy in lowering hospitalization and death rates [<xref rid="B135-vaccines-12-01220" ref-type="bibr">135</xref>].</p><p>SARS-CoV-2 enters the host cells via the ACE2 receptor, which is highly expressed in the respiratory tract. To block viral entry, most mAbs are designed to target epitopes on the viral spike (S) glycoprotein, specifically the S1 and S2 subunits. Since spike protein exhibits high mutation rates, the efficacy of mAbs depends on the circulating variant. Bamlanivimab, casirivimab, and imdevimab were the first mAbs approved by the FDA for emergency use, and they have been shown to reduce hospitalization and mortality compared to placebo [<xref rid="B136-vaccines-12-01220" ref-type="bibr">136</xref>,<xref rid="B137-vaccines-12-01220" ref-type="bibr">137</xref>,<xref rid="B138-vaccines-12-01220" ref-type="bibr">138</xref>,<xref rid="B139-vaccines-12-01220" ref-type="bibr">139</xref>]. Administering these mAbs in combination rather than individually has resulted in more positive clinical outcomes and offers a strategy for overcoming resistance [<xref rid="B140-vaccines-12-01220" ref-type="bibr">140</xref>].</p><p>Clinical trials have demonstrated that the combination of casirivimab and imdevimab (REGEN-COV), when administered within five days of infection, can reduce hospitalization by approximately 56.4%, decrease disease severity by 59.2%, and prevent death by 93.5% over a 28-day treatment period [<xref rid="B138-vaccines-12-01220" ref-type="bibr">138</xref>,<xref rid="B141-vaccines-12-01220" ref-type="bibr">141</xref>]. However, the emergence of new variants, such as Omicron and its sublineages, has led to resistance against many of these early mAbs, resulting in the withdrawal of their EUA.</p><p>Recently, bebatelovimab has become important owing to its efficacy against all known COVID-19 variants, including Omicron, prompting EUA by the FDA and pending approval by the European Medicines Agency (EMA) [<xref rid="B142-vaccines-12-01220" ref-type="bibr">142</xref>,<xref rid="B143-vaccines-12-01220" ref-type="bibr">143</xref>]. While mAbs provide considerable protection and positive recovery outcomes, the ongoing emergence of COVID-19 variants requires careful consideration of the potential for resistance in the context of a rapidly evolving pandemic [<xref rid="B144-vaccines-12-01220" ref-type="bibr">144</xref>,<xref rid="B145-vaccines-12-01220" ref-type="bibr">145</xref>].</p><p>Although influenza and coronaviruses are RVs that primarily infect the respiratory tract, their extrapulmonary effects can impact the gastrointestinal, cardiac, neurological, and endocrine systems. It is essential to determine whether these effects are caused directly by viral infection, inflammation, or an immune system-based cytokine storm before optimizing antiviral therapies.</p><p>Ongoing surveillance of RVs, along with comprehensive studies, can help mitigate future epidemics or pandemics. By curbing the transmission and implementing strategic medical countermeasures, such as a combination of antivirals and vaccines, the human immune system can be better equipped to handle emerging treats.</p><table-wrap position="anchor" id="vaccines-12-01220-t003" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of approved antiviral treatments for Coronavirus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antiviral Agents</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Category</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indication</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Remdesivir (Veklury<sup>&#174;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits RNA-dependent RNA polymerase (RdRp)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenosine analog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalized and non-hospitalized adults and pediatrics at high risk of progression to severe disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FDA approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-vaccines-12-01220" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Molnupiravir (Lagevrio<sup>&#174;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces viral RNA mutagenesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults with mild-to-moderate COVID-19 are at high risk of progression to severe disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EUA and approved in many countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-vaccines-12-01220" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nirmatrelvir + Ritonavir (Paxlovid<sup>&#174;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protease inhibitor (inhibits viral replication)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mpro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate COVID-19 patients at risk of progression to severe disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in the United States, the United Kingdom, and EU; EUA in many countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B148-vaccines-12-01220" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bebtelovimab</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 (all variants)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody (targets spike protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment of COVID-19 in non-hospitalized patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EUA by US FDA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-vaccines-12-01220" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sotrovimab (Xevudy)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody (targets highly conserved sequences)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate COVID-19 patients at risk of progression to severe disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EUA or approved in many countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B149-vaccines-12-01220" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Casirivimab and imdevimab (REGEN-COV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody (targets spike protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous (IV) and subcutaneous (SC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mAb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S-protein</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild or moderate COVID-19, conditional approval for the prophylaxis and treatment of acute COVID-19 in the United Kingdom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EUA in many countries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-vaccines-12-01220" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ensitrelvir (Xocova)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3C-like protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small molecule</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mpro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">May be effective in treating smell and taste loss from the COVID-19 infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in Japan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-vaccines-12-01220" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simnotrelvir + ritonavir (Xiannuoxin)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small molecule</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mpro</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild-to-moderate COVID-19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B151-vaccines-12-01220" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VV116</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analogue antiviral drug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Small molecule</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-hospitalized adults with mild-to-moderate disease</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved in China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-vaccines-12-01220" ref-type="bibr">152</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>EUA: Emergency Use Authorization.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="sec6-vaccines-12-01220"><title>6. Clinical Studies and Approval of Antiviral Treatments for RVs</title><p>To reduce mortality rates and combat RV infections, it is essential for medical professionals and scientists to develop effective antivirals and vaccines. A major challenge in this endeavor is the need for continuous monitoring and distribution of drug supplies through an expansive global network of institutions, especially as disease rates fluctuate globally. This necessitates collaboration among healthcare providers, pharmaceutical companies, and government bodies to ensure that treatments are both effective and accessible. <xref rid="vaccines-12-01220-t004" ref-type="table">Table 4</xref> provides a summary of the approved antiviral treatments as well as ongoing clinical trials targeting RV infections, highlighting the latest progress in combating these diseases.</p></sec><sec id="sec7-vaccines-12-01220"><title>7. Antiviral Vaccines for Respiratory Virus: Influenza and Coronavirus</title><p>Vaccination&#8217;s two primary purposes are to protect against infectious diseases and to stimulate the immune system. However, the efficacy and effectiveness of vaccines vary depending on the type of infection and the specific product. Historically, traditional vaccines were developed by inactivating or attenuating the corresponding pathogen, which effectively curtailed the spread of infections and contributed to the eradication of diseases. However, there are still concerns with conventional vaccines, such as the inclusion of unwanted contaminants, structural alterations in protein-laden antigens, and the possibility that inactivated antigens may not always elicit a strong immune response [<xref rid="B153-vaccines-12-01220" ref-type="bibr">153</xref>,<xref rid="B154-vaccines-12-01220" ref-type="bibr">154</xref>,<xref rid="B155-vaccines-12-01220" ref-type="bibr">155</xref>].</p><p>In a pandemic crisis, producing billions of safe and effective vaccine doses within a shorter timeframe poses significant scientific challenges, which hinge on three key factors. First, selecting the appropriate scientific approach to produce absolute immunogenicity is essential for the complete eradication of viral reservoirs. Second, an effective platform must be available for mass production of vaccines. Third, the timely distribution of vaccines to all regions of the world is necessary. The primary goal of vaccine development is to create the safest vaccines that elicit a robust immune response. Achieving this goal depends on unprecedented cooperation between industries, researchers, and regulators [<xref rid="B156-vaccines-12-01220" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-12-01220" ref-type="bibr">157</xref>,<xref rid="B158-vaccines-12-01220" ref-type="bibr">158</xref>].</p><p>Vaccination is the sole course of action for achieving herd immunity, which is crucial in halting the spread of viruses during epidemics or pandemics [<xref rid="B155-vaccines-12-01220" ref-type="bibr">155</xref>]. Under normal circumstances, vaccines take several years to develop, with only about 10% of vaccines receiving authorization for commercialization. Typically, clinical development and commercialization of vaccines take five to ten years [<xref rid="B159-vaccines-12-01220" ref-type="bibr">159</xref>]. However, recent pandemics have placed immense socioeconomic pressure on accelerating vaccine development from classical approaches to more novel nucleic acid-based vaccines [<xref rid="B155-vaccines-12-01220" ref-type="bibr">155</xref>].</p><p>Before developing a vaccine, certain criteria must be carefully evaluated, starting from target antigen detection, mode of administration, animal models, scale-up, production, manufacturing, storage, and transportation [<xref rid="B160-vaccines-12-01220" ref-type="bibr">160</xref>]. Selecting the right vaccine type&#8212;along with the appropriate adjuvants, excipients, dosage, optimal route of administration, and booster doses&#8212;can significantly improve vaccine effectiveness against RV infections [<xref rid="B161-vaccines-12-01220" ref-type="bibr">161</xref>]. Traditional vaccines include inactivated viruses, live attenuated vaccines, protein subunit vaccines, and virus-like particles, whereas new-generation vaccines include recombinant viral vector vaccines, nucleic acid-based vaccines, and antigen-presenting cell-based vaccines [<xref rid="B162-vaccines-12-01220" ref-type="bibr">162</xref>]. Each class of vaccines has its own advantages, including genetic manipulation, strong immune response, prolonged stability, and convenience for large-scale manufacturing.</p><sec id="sec7dot1-vaccines-12-01220"><title>7.1. Vaccine Types</title><sec id="sec7dot1dot1-vaccines-12-01220"><title>7.1.1. Whole Pathogen Vaccines</title><p>Conventional vaccines against whole pathogens comprise either inactivated/killed or attenuated/live pathogens [<xref rid="B163-vaccines-12-01220" ref-type="bibr">163</xref>]. Attenuation significantly reduces the viral virulence and replicability of pathogens. However, in rare cases&#8212;particularly in immunocompromised patients&#8212;attenuated whole pathogen vaccines can cause infection, exhibit toxicity, or trigger unwanted immune responses [<xref rid="B164-vaccines-12-01220" ref-type="bibr">164</xref>]. Inactivated vaccines contain whole viruses that have been destroyed and are unable to replicate. As a result, they do not constantly stimulate the immune system, which may necessitate multiple doses and/or the use of an external adjuvant to elicit the desired immune response [<xref rid="B165-vaccines-12-01220" ref-type="bibr">165</xref>]. One drawback of using whole viruses is that they may produce infectious particles or degrade viral antigens and epitopes during the inactivation process, potentially reducing their effectiveness [<xref rid="B166-vaccines-12-01220" ref-type="bibr">166</xref>].</p></sec><sec id="sec7dot1dot2-vaccines-12-01220"><title>7.1.2. Subunit Vaccines</title><p>Subunit vaccines are composed of specific virus components, such as proteins, peptides, or polysaccharides, which can trigger protective immune responses [<xref rid="B167-vaccines-12-01220" ref-type="bibr">167</xref>]. It has been shown that the particle size in subunit vaccine formulations plays a critical role in determining vaccine efficiency [<xref rid="B168-vaccines-12-01220" ref-type="bibr">168</xref>]. Proteins, nucleic acids, and polysaccharides can all be employed as antigens. Subunit vaccines are safer for use in immunocompromised individuals and carry a lower risk of adverse effects compared to whole pathogen vaccines. However, due to the smaller size of the antigenic components, they may generate lower immunogenicity, necessitating the use of adjuvants and specialized delivery systems to enhance immune responses [<xref rid="B169-vaccines-12-01220" ref-type="bibr">169</xref>].</p></sec><sec id="sec7dot1dot3-vaccines-12-01220"><title>7.1.3. Nucleic Acid Vaccines</title><p>DNA vaccines contain target protein-encoding DNA and delivery vectors that allow vaccine components to reach the cell nucleus, where DNA is translated into mRNA for protein biosynthesis. DNA vaccines have the potential to stimulate both B cells and T cells in the immune system, but delivering DNA into the nucleus remains a significant challenge in the development of these vaccines. Recent advancements have focused on optimizing DNA constructs and delivery vectors to improve the efficacy and safety of DNA vaccines [<xref rid="B170-vaccines-12-01220" ref-type="bibr">170</xref>,<xref rid="B171-vaccines-12-01220" ref-type="bibr">171</xref>,<xref rid="B172-vaccines-12-01220" ref-type="bibr">172</xref>].</p><p>Another novel approach to vaccination is the use of genetic material encoding the antigen(s) against which an immune response is desired [<xref rid="B173-vaccines-12-01220" ref-type="bibr">173</xref>]. The genetic material is introduced into human cells, which then produce target proteins that serve as antigens to elicit an immune response. A notable recent development in the field is the mRNA vaccines [<xref rid="B174-vaccines-12-01220" ref-type="bibr">174</xref>,<xref rid="B175-vaccines-12-01220" ref-type="bibr">175</xref>,<xref rid="B176-vaccines-12-01220" ref-type="bibr">176</xref>]. This strategy has demonstrated significant promise, particularly in the contest of the COVID-19 pandemic [<xref rid="B177-vaccines-12-01220" ref-type="bibr">177</xref>,<xref rid="B178-vaccines-12-01220" ref-type="bibr">178</xref>].</p></sec></sec><sec id="sec7dot2-vaccines-12-01220"><title>7.2. Viral Vaccines Combating Influenza Virus</title><p>Of all RVs, the influenza virus not only causes seasonal episodes but also triggers epidemic and pandemic outbreaks, leading to significant illness and fatalities worldwide. Over the last century, there have been four major influenza-related pandemics: the 1918 A/H1N1 pandemic, often referred to as the &#8220;Spanish Flu&#8221;, the 1957 A/H2N2 reassortment of human and avian viruses originating in China, the 1968 A/H3N2 influenza that struck Hong Kong, and the most recent A/(H1N1) pdm09 variant that emerged in North America in April 2009 [<xref rid="B179-vaccines-12-01220" ref-type="bibr">179</xref>]. Each of these four pandemics resulted in at least 10,000 deaths, underscoring the urgent need for the development of universal influenza vaccines [<xref rid="B180-vaccines-12-01220" ref-type="bibr">180</xref>].</p><p>Seasonal influenza epidemics cause an estimated 290,000 and 650,000 respiratory-related deaths and between 3 and 5 million cases of severe illnesses globally each year [<xref rid="B181-vaccines-12-01220" ref-type="bibr">181</xref>]. Influenza epidemics, commonly referred to as the seasonal flu, are caused by novel influenza strains that emerge intermittently every two to five years. These outbreaks, which may be influenced by weather and climate, can last from three to six months depending on the region [<xref rid="B182-vaccines-12-01220" ref-type="bibr">182</xref>,<xref rid="B183-vaccines-12-01220" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-12-01220" ref-type="bibr">184</xref>]. The influenza virus is able to evade the human immune system through unique mutations in its surface glycoproteins, HA and NA [<xref rid="B185-vaccines-12-01220" ref-type="bibr">185</xref>]. This is why neither spontaneous infection nor vaccination can provide lifelong immunity against the virus [<xref rid="B186-vaccines-12-01220" ref-type="bibr">186</xref>].</p><p>Currently, three types of influenza vaccines are used globally: recombinant HA vaccines, live attenuated influenza vaccines (LAIVs), and inactivated influenza vaccines (IIVs) [<xref rid="B187-vaccines-12-01220" ref-type="bibr">187</xref>]. Due to the limited duration of immunity and the need to account for the antigenic variations of circulating viruses, all influenza vaccinations need to be updated annually [<xref rid="B188-vaccines-12-01220" ref-type="bibr">188</xref>].</p><sec id="sec7dot2dot1-vaccines-12-01220"><title>7.2.1. Inactivated Influenza Vaccine</title><p>The inactivated viral vaccine, which holds the largest proportion in the global flu vaccine market, is widely used due to its high safety and comparatively low production costs [<xref rid="B189-vaccines-12-01220" ref-type="bibr">189</xref>]. This type of vaccine is typically produced by cultivating the virus in cultured mammalian cells or embryonated chicken eggs [<xref rid="B190-vaccines-12-01220" ref-type="bibr">190</xref>,<xref rid="B191-vaccines-12-01220" ref-type="bibr">191</xref>]. Inactivated influenza vaccines can induce both systemic and local immunity, yet booster shots may be required to maintain adequate antibody titers [<xref rid="B192-vaccines-12-01220" ref-type="bibr">192</xref>]. These vaccines can be further categorized into three types based on production techniques: whole-virus inactivated vaccine, split-virus inactivated vaccine, and subunit inactivated vaccine [<xref rid="B187-vaccines-12-01220" ref-type="bibr">187</xref>]. Split-virus and subunit vaccines are more frequently used than whole-virus vaccines due to their similar immunogenicity and reduced risk of adverse reactions [<xref rid="B193-vaccines-12-01220" ref-type="bibr">193</xref>].</p></sec><sec id="sec7dot2dot2-vaccines-12-01220"><title>7.2.2. Live Attenuated Influenza Vaccines</title><p>LAIVs stimulates both humoral and cellular immunity by mimicking natural infection and immunization without causing significant harm to the recipient [<xref rid="B194-vaccines-12-01220" ref-type="bibr">194</xref>,<xref rid="B195-vaccines-12-01220" ref-type="bibr">195</xref>]. These vaccines use a temperature-sensitive, cold-adapted virus strain that replicates preferentially in the nasopharynx but is unable to reproduce efficiently in the warmer environment of the lower respiratory tract [<xref rid="B196-vaccines-12-01220" ref-type="bibr">196</xref>,<xref rid="B197-vaccines-12-01220" ref-type="bibr">197</xref>]. However, due to the risk associated with live viruses, LAIVs are not recommended for immunocompromised individuals or those in close contact with them [<xref rid="B187-vaccines-12-01220" ref-type="bibr">187</xref>].</p></sec><sec id="sec7dot2dot3-vaccines-12-01220"><title>7.2.3. Recombinant HA Vaccine</title><p>Recombinant HA vaccines are produced by cloning the DNA encoding HA into a vector, such as a baculovirus, and generating recombinant viruses in insect cells. This method offers high production capacity at low cost [<xref rid="B198-vaccines-12-01220" ref-type="bibr">198</xref>,<xref rid="B199-vaccines-12-01220" ref-type="bibr">199</xref>,<xref rid="B200-vaccines-12-01220" ref-type="bibr">200</xref>]. A key advantage of recombinant HA vaccines is that they avoid unwanted mutations from egg adaptation, making them a preferable option for individuals allergic to eggs [<xref rid="B200-vaccines-12-01220" ref-type="bibr">200</xref>]. While the mechanism of action for the recombinant HA vaccine is similar to that of the inactivated influenza vaccine, the recombinant HA vaccine requires only one-third of the HA to elicit the same antibody response due to its higher immunogenicity [<xref rid="B201-vaccines-12-01220" ref-type="bibr">201</xref>]. Additionally, recombinant HA vaccines are most suitable for pandemic preparedness because they can be produced faster and are safer against highly pathogenic viruses. However, they are currently only approved for use in adults, as they have been found to be ineffective in children [<xref rid="B202-vaccines-12-01220" ref-type="bibr">202</xref>].</p><p>Regular vaccination against influenza and its variants is essential, as immunity wanes over time. Annual influenza vaccination helps maintain protection. The effectiveness of the seasonal vaccine depends on how well the vaccine strain matches the circulating virus strain [<xref rid="B203-vaccines-12-01220" ref-type="bibr">203</xref>,<xref rid="B204-vaccines-12-01220" ref-type="bibr">204</xref>]. Although limitations exist regarding vaccine effectiveness, advancements in vaccine technologies and increased production of more efficacious vaccines have helped reduce the burden of disease and prevent outbreaks [<xref rid="B153-vaccines-12-01220" ref-type="bibr">153</xref>]. A list of various influenza virus vaccines approved for commercialization is presented in <xref rid="vaccines-12-01220-t005" ref-type="table">Table 5</xref>.</p></sec></sec><sec id="sec7dot3-vaccines-12-01220"><title>7.3. Viral Vaccines Combating Coronavirus</title><p>The recent SARS-CoV-2 pandemic created a global health crisis, overwhelming healthcare systems in many countries for several months. In response, vaccines became urgently necessary to reduce fatalities and achieve herd immunity [<xref rid="B205-vaccines-12-01220" ref-type="bibr">205</xref>]. The collaboration between academic institutions, biotechnology companies, pharmaceutical firms, and government organizations led to the EUA of several vaccines, which demonstrated credible safety and efficacy in preventing the spread of the disease. These EUA-approved vaccines played a crucial role in mitigating the pandemic and reducing loss of life [<xref rid="B155-vaccines-12-01220" ref-type="bibr">155</xref>].</p><p>According to the latest WHO reports, more than 50 COVID-19 vaccines of various genres have been approved, 183 vaccine candidates are being tested in clinical trials, and 199 are in the preclinical stage [<xref rid="B206-vaccines-12-01220" ref-type="bibr">206</xref>].</p><sec id="sec7dot3dot1-vaccines-12-01220"><title>7.3.1. Inactivated Whole Virus Vaccines</title><p>The traditional approach to developing a whole virus vaccine involves administering an inactivated or live attenuated form of the virus [<xref rid="B207-vaccines-12-01220" ref-type="bibr">207</xref>]. For inactivated whole-virus vaccines, the SARS-CoV-2 cultivated in cells is inactivated using agents such as formaldehyde or glutaraldehyde or through exposure to UV or gamma radiation [<xref rid="B208-vaccines-12-01220" ref-type="bibr">208</xref>]. As of right now, 11 inactivated COVID-19 vaccines have received approval across the globe [<xref rid="B209-vaccines-12-01220" ref-type="bibr">209</xref>].</p><p>The Covilo vaccine, developed by Sinopharm (Beijing, Chia), is the most widely authorized inactivated COVID-19 vaccine, receiving approval in 93 countries. The vaccine contains two SARS-CoV-2 strains, WIV04 and HB02, grown in the Vero cell line and inactivated using &#946;-propiolactone. Aluminum hydroxide is used as an adjuvant. The estimated vaccine efficacy against the symptomatic COVID 2019 was 72.8% for WIV04, 78.1% for HB02, and 79% against severe illness or hospitalization [<xref rid="B210-vaccines-12-01220" ref-type="bibr">210</xref>,<xref rid="B211-vaccines-12-01220" ref-type="bibr">211</xref>,<xref rid="B212-vaccines-12-01220" ref-type="bibr">212</xref>].</p><p>Another inactivated vaccine, CoronaVac, was developed by Sinovac Life Sciences Co. (Beijing, China); this vaccine uses the SARS-CoV-2 strain CN02, also cultured in Vero cell line and inactivated with &#946;-propiolactone. Like Covilo, it contains aluminum hydroxide as an adjuvant to boost the immune response. CoronaVac has been approved in 56 countries, and its efficacy varied from 50% in symptomatic patients to 83.5% in asymptomatic patients [<xref rid="B213-vaccines-12-01220" ref-type="bibr">213</xref>].</p><p>In India, Covaxin<sup>&#174;</sup> (BBV152), developed by Bharat Biotech (Hyderabad, India), was the second-most frequently administered vaccine. It is a &#946;-propiolactone inactivated vaccine, incorporating the whole virion along with an adjuvant made of imidazo-quinoline gallamide adsorbed on alum, which enhances vaccine antigen delivery to lymph nodes without causing systemic influx. The vaccine is based on the genetically stable strain NIV-2020-770, which contains the Asp614Gly mutation [<xref rid="B214-vaccines-12-01220" ref-type="bibr">214</xref>]. Covaxin demonstrated inconsistent seroconversion rates, reaching 90% in cohorts tested closer to the Omicron wave [<xref rid="B215-vaccines-12-01220" ref-type="bibr">215</xref>]. The vaccine stimulates follicular T helper cells, which aid in boosting B cell responses, generating strong immunological memory against SARS-CoV-2 and other variants of concerns [<xref rid="B215-vaccines-12-01220" ref-type="bibr">215</xref>].</p><p>The Chumakov Centre (Moscow, Russia), part of the Russian Academy of Sciences, developed the KoviVac vaccine, which has been approved in Russia, Belarus, and Cambodia. KoviVac uses the SARS-CoV-2 strain AYDAR-1, inactivated with &#946;-propiolactone, with aluminum hydroxide as an adjuvant. In clinical trials, seronegative participants showed an 86.9% seroconversion rate. The vaccine was found to have good safety and tolerability [<xref rid="B216-vaccines-12-01220" ref-type="bibr">216</xref>,<xref rid="B217-vaccines-12-01220" ref-type="bibr">217</xref>].</p></sec><sec id="sec7dot3dot2-vaccines-12-01220"><title>7.3.2. Protein Subunit Vaccine</title><p>Immunizations against a wide range of infections are produced using protein subunits made up of one or more distinct viral antigens [<xref rid="B218-vaccines-12-01220" ref-type="bibr">218</xref>]. These vaccines usually require an appropriate adjuvant when administered to humans to trigger a robust immune response. Subunit vaccine formulations combine purified antigens with powerful adjuvants to enhance immunogenicity [<xref rid="B219-vaccines-12-01220" ref-type="bibr">219</xref>]. As of now, 19 protein-based subunit COVID-19 vaccines have received global approval [<xref rid="B209-vaccines-12-01220" ref-type="bibr">209</xref>].</p><p>Novavax (Gaithersburg, MD, USA) developed the NVX-CoV2373, also known as Nuvaxovid, which is the most widely authorized protein subunit COVID-19 vaccine, approved in 40 countries. Nuvaxovid is a recombinant DNA product made in an insect cell line derived from Sf9 cells of the <italic toggle="yes">Spodoptera frugiperda</italic> species. It contains the S protein from the original SARS-CoV-2 virus strain. The vaccine also includes Matrix-M<sup>TM</sup>, a proprietary saponin-based adjuvant, and polysorbate 80 (PS80) to stabilize nanoparticles. In clinical trials conducted in the United States and Mexico, the vaccine showed efficacy of 90.4%, while trials in the United Kingdom demonstrated an efficacy of 89.7%. Adverse reactions, mostly mild to moderate, were frequent after the second dose and typically resolved within days [<xref rid="B209-vaccines-12-01220" ref-type="bibr">209</xref>,<xref rid="B220-vaccines-12-01220" ref-type="bibr">220</xref>,<xref rid="B221-vaccines-12-01220" ref-type="bibr">221</xref>].</p><p>Another subunit COVID-19 vaccine, VidPrevtyn Beta, was developed by Sanofi (Lyon, France)/GSK (Rixensart, Belgium) and has been authorized in 30 countries. This vaccine uses the spike protein derived from the Beta variant (B.1.351 strain) of SARS-CoV-2, produced using recombinant DNA technology through a baculovirus expression system in insect cells from <italic toggle="yes">Spodoptera frugiperda</italic>. To boost the immune response, AS03, a combination of squalene, DL-&#945;-tocopherol, and polysorbate 80, is used as an adjuvant. Comparative research indicated that the VidPrevtyn Beta booster showed efficacy comparable to the mRNA vaccine, including against the Omicron BA.1 subvariant of SARS-CoV-2 [<xref rid="B222-vaccines-12-01220" ref-type="bibr">222</xref>,<xref rid="B223-vaccines-12-01220" ref-type="bibr">223</xref>].</p></sec><sec id="sec7dot3dot3-vaccines-12-01220"><title>7.3.3. mRNA Vaccines</title><p>mRNA vaccines employ a novel strategy by delivering a nucleotide sequence encoding the antigen(s) selected for their ability to elicit a protective immune response [<xref rid="B177-vaccines-12-01220" ref-type="bibr">177</xref>,<xref rid="B224-vaccines-12-01220" ref-type="bibr">224</xref>]. Although research on this technology has been going on for several years and there are potential vaccines for other infectious illnesses, the COVID-19 mRNA vaccines are the first to be approved for widespread use in public health programs [<xref rid="B225-vaccines-12-01220" ref-type="bibr">225</xref>,<xref rid="B226-vaccines-12-01220" ref-type="bibr">226</xref>]. These vaccines contain messenger RNA (mRNA) that codes for the S protein of SARS-CoV-2, the primary surface protein that binds to host cell receptors. Various approaches have been used to deliver mRNA to cells, including polymer-based nanoparticle formulation, lipid encapsulation, and incorporation of 5&#8242;-cap or 3&#8242;poly-A sequences for RNA stability and delivery. Once inside the cells, the mRNA is translated into target antigen using the cell&#8217;s machinery, which triggers an immune response [<xref rid="B227-vaccines-12-01220" ref-type="bibr">227</xref>]. Currently, four companies have produced mRNA COVID-19 vaccines, all of which are approved in at least one country.</p><p>The Comirnaty vaccine, developed by Pfizer (New York, NY, USA) and BioNTech (Mainz, Germany), has been approved in 149 countries. It comprises single-stranded, 5&#8217; capped mRNA that encodes the SARS-CoV-2 virus&#8217;s S protein, produced through cell-free in vitro transcription using a DNA template. Clinical trials demonstrated that Comirnaty has an efficacy of 94.6% (95% CI: 89.9&#8211;97.3) against COVID-19 in adults and adolescents aged 16 and older. It also showed 100% efficacy against severe COVID-19 requiring hospitalization and COVID-19-related death. However, the emergence of new SARS-CoV-2 variants has reduced its effectiveness, prompting Pfizer and BioNTech to develop modified vaccines that include mRNA specific for the Omicron BA.1 and BA.4/BA.5 strains [<xref rid="B228-vaccines-12-01220" ref-type="bibr">228</xref>,<xref rid="B229-vaccines-12-01220" ref-type="bibr">229</xref>].</p><p>Spikevax, the mRNA COVID-19 vaccine developed by Moderna (Cambridge, MA, USA) has been approved in 88 countries. Spikevax encodes the S protein of the SARS CoV-2 virus using single-stranded, 5&#8217; capped mRNA (known as elasomeran), which is produced via in vitro transcription on a DNA template. The mRNA is enclosed within lipid nanoparticles (LNPs), specifically SM-102, for delivery. In clinical trials, the vaccine demonstrated an efficacy of 94.1% (95% CI: 89.3&#8211;96.8) against symptomatic COVID-19 and 90.9% efficacy in patients at risk of severe COVID-19, including those with comorbidities and immunocompromised individuals [<xref rid="B230-vaccines-12-01220" ref-type="bibr">230</xref>,<xref rid="B231-vaccines-12-01220" ref-type="bibr">231</xref>].</p></sec><sec id="sec7dot3dot4-vaccines-12-01220"><title>7.3.4. Viral Vector-Based Vaccines</title><p>Viral vector-based COVID-19 vaccines have garnered significant attention due to their ability to effectively deliver and express SARS-CoV-2 proteins or their epitopes as antigens [<xref rid="B232-vaccines-12-01220" ref-type="bibr">232</xref>]. These vaccines use viral vectors to carry the antigen, and they come in two varieties: non-replicating and self-replicating. After vaccination, the antigen is produced, triggering a robust humoral and cellular immune response that mimics a natural infection. Replicating vector vaccines can be administered at lower doses while still achieving a strong effect, thereby improving the safety and efficacy profiles of these vaccines [<xref rid="B233-vaccines-12-01220" ref-type="bibr">233</xref>].</p><p>The Oxford/AstraZeneca vaccine, Vaxzevria (also known as AZD1222 and ChAdOx1 nCoV-19), has been approved in 149 countries. It is made by chimpanzee adenovirus (ChAdOx1-S) that encodes the SARS-CoV-2 spike glycoprotein and is produced in genetically modified HEK 293 cells. According to studies conducted in Brazil (COV003) and the United Kingdom (COV002), the vaccine&#8217;s efficacy was approximately 60%. Another study, which included 21% of participants aged 65 and older and was carried out in the United States, Peru, and Chile, found that individuals who received two doses of the vaccine (with the second dose administered four weeks after the first) had a 74% lower incidence of symptomatic COVID-19 compared to the control group [<xref rid="B234-vaccines-12-01220" ref-type="bibr">234</xref>,<xref rid="B235-vaccines-12-01220" ref-type="bibr">235</xref>].</p><p>The Janssen (Johnson &amp; Johnson, New Brunswick, NJ, USA) vaccine, Jcovden (also known as Ad26.COV2.S, Ad26COVS1, and JNJ-78436735), has been approved in 113 nations. It utilizes adenovirus type 26, which encodes the SARS-CoV-2 spike glycoprotein and is produced using the PER C6 TetR cell line derived from human embryonic retinal tissue. The vaccine demonstrated 66.9% efficacy after a single dose 14 days post-immunization and 66.1% efficacy 28 days post-immunization. Revised assessments indicated that the vaccine&#8217;s effectiveness against symptomatic and severe COVID-19 was 76.1% after 14 days. The booster dose administered at least two months after the initial vaccination course showed an increase in neutralizing and protein S-binding antibodies, confirming the effectiveness of booster vaccination in enhancing immunity [<xref rid="B236-vaccines-12-01220" ref-type="bibr">236</xref>,<xref rid="B237-vaccines-12-01220" ref-type="bibr">237</xref>].</p><p>The Sputnik V vaccine, also known as Gam-COVID-Vac, was developed by the Russian Gamaleya National Center of Epidemiology and Microbiology and has been approved in 75 countries. It uses a combination of two adenovirus vectors&#8212;rAD26 for the first dose and rAd5 for the second&#8212;to deliver the full-length SARS-CoV-2 S glycoprotein gene, overcoming the population&#8217;s pre-existing immunity to adenoviruses. Phase III interim findings showed that the vaccine&#8217;s efficacy was 91.6% after 21 days from the first dose and was 100% effective in preventing severe forms of COVID-19 [<xref rid="B238-vaccines-12-01220" ref-type="bibr">238</xref>,<xref rid="B239-vaccines-12-01220" ref-type="bibr">239</xref>].</p><p>With the ongoing threat of emerging variants of concern (VOCs) and variants of interest (VOIs), developing innovative vaccines that target specific alterations in viral surface proteins responsible for immune escape will be crucial for countering new variants [<xref rid="B240-vaccines-12-01220" ref-type="bibr">240</xref>]. A list of vaccines developed against SARS-CoV-2 and approved for commercialization in various countries is presented in <xref rid="vaccines-12-01220-t006" ref-type="table">Table 6</xref>.</p></sec></sec></sec><sec id="sec8-vaccines-12-01220"><title>8. Lesson(s) Learnt from These Outbreaks</title><p>RVs, such as influenza and coronaviruses, can mutate rapidly and spread globally, ultimately leading to pandemics. These pandemics are unpredictable due to antigenic drift, cross-species transmission, and the emergence of new strains and variants capable of infecting humans. Several factors contribute to the seasonality of RVs, including colder temperatures, changes in host susceptibility, and environmental conditions that favor viral spread [<xref rid="B6-vaccines-12-01220" ref-type="bibr">6</xref>]. Compared to influenza and other seasonal RVs, coronaviruses are more transmissible, causing substantial morbidity and mortality [<xref rid="B241-vaccines-12-01220" ref-type="bibr">241</xref>,<xref rid="B242-vaccines-12-01220" ref-type="bibr">242</xref>]. Furthermore, the emergence of novel variants has prolonged the duration of pandemics.</p><p>Existing antivirals, vaccines, and drugs are not always effective against all variants, and controlling viral transmission during a pandemic remains a significant challenge. To mitigate future outbreaks, new drugs with broad-spectrum antiviral activity must be developed to reduce both morbidity and mortality. Targeting highly conserved viral or host factors across all variants may inhibit viral replication and provide broad-spectrum antiviral activity against emerging viruses. Although emerging variants complicate antiviral therapy development, targeting conserved host factors during viral infection may help circumvent these challenges. However, developing therapies against host proteins requires extensive study to avoid disrupting critical physiological processes and to minimize side effects [<xref rid="B243-vaccines-12-01220" ref-type="bibr">243</xref>,<xref rid="B244-vaccines-12-01220" ref-type="bibr">244</xref>,<xref rid="B245-vaccines-12-01220" ref-type="bibr">245</xref>].</p><p>Therapeutic antibodies, such as mAbs, are effective against RV infections. However, the efficacy may be compromised by viral mutations, particularly in the receptor-binding domain, rendering some mAbs less effective against emerging variants. Broad-spectrum mAbs that target conserved viral epitopes must be developed to maintain neutralizing activity. While vaccines and antibody therapies can augment immune responses, continuous viral mutations can lead to immune evasion, reducing the effectiveness of current vaccines and therapies [<xref rid="B246-vaccines-12-01220" ref-type="bibr">246</xref>,<xref rid="B247-vaccines-12-01220" ref-type="bibr">247</xref>].</p><p>Repurposing existing drugs with proven safety profiles has emerged as a rapid strategy to address emerging RVs, as these drugs have known mechanisms of action and side-effect mitigation strategies [<xref rid="B248-vaccines-12-01220" ref-type="bibr">248</xref>]. Constant surveillance of emerging variants, antiviral efficacy, and vaccine performance is crucial to overcoming these obstacles. Given the unpredictability of future outbreaks, continuous vigilance and forecasting of pathogenic RVs are required to develop countermeasures, including broad-spectrum antivirals and vaccines [<xref rid="B249-vaccines-12-01220" ref-type="bibr">249</xref>]. Future health threats from pandemics must be addressed through risk assessments, enhanced international collaboration for epidemic and pandemic surveillance, and improved screening and diagnostics for pan-respiratory viruses.</p></sec><sec id="sec9-vaccines-12-01220"><title>9. Combating Future RV Outbreak</title><p>RVs possess a remarkable capacity to cause epidemics and pandemics due to their high mutation rates, potential for cross-species transmission, broad host range, rapid replication, contagious nature, and the lack of herd immunity in human populations. Although humans have experienced various RV pandemics and epidemics, highly effective treatment options remain limited. Understanding the biology and genomics of RVs has facilitated the development of some treatments, but these are often delayed during pandemics. Over the past two decades, influenza has caused one pandemic (swine flu, 2009), while coronaviruses have caused two epidemics (SARS, 2003; MERS, 2012) and one pandemic (COVID-19, 2019). Seasonal and climate changes continue to drive constant mutations in RVs, increasing the occurrence of cross-species infections in humans [<xref rid="B250-vaccines-12-01220" ref-type="bibr">250</xref>,<xref rid="B251-vaccines-12-01220" ref-type="bibr">251</xref>].</p><p>Recent pandemics have highlighted the immense socioeconomic burden of such outbreaks, underscoring the need for proactive antiviral development. Treatments focused on RVs that pose significant public health risks are crucial. Antiviral therapies targeting different respiratory virus genera, which vary in tissue tropism, clinical signs, and transmission profiles, are essential in preventing epidemics from escalating into pandemics. Host-directed antivirals may be particularly effective against a wide range of viruses and could prevent an epidemic from becoming a pandemic [<xref rid="B252-vaccines-12-01220" ref-type="bibr">252</xref>,<xref rid="B253-vaccines-12-01220" ref-type="bibr">253</xref>].</p><p>While annual vaccinations can control seasonal RV infections at both individual and community levels, vaccines alone cannot halt pandemics. Antigenic drift and mutations can reduce vaccine efficacy, enabling the emergence of highly virulent virus strains capable of infecting large populations. Therefore, the development of effective treatments for RVs is essential. Managing influenza and coronavirus outbreaks requires enhanced preparedness to reduce the overall burden of these infections. Key measures include prompt diagnostics, tailored treatment plans, and expanded vaccination programs targeting both coronaviruses and influenza viruses [<xref rid="B254-vaccines-12-01220" ref-type="bibr">254</xref>,<xref rid="B255-vaccines-12-01220" ref-type="bibr">255</xref>].</p><p>Proactive surveillance, combined with comprehensive mechanistic control strategies, can help manage pandemics effectively. Past outbreaks have demonstrated the need to improve techniques for characterizing antigenic properties, identifying emerging strains, and understanding the mechanisms of infection and disease pathophysiology. Developing countermeasures to protect populations vulnerable to RVs remains a critical challenge [<xref rid="B256-vaccines-12-01220" ref-type="bibr">256</xref>].</p><p>Future respiratory virus outbreaks could involve viruses that are symptomatically or antigenically similar to those of past pandemics, posing even greater threats to human populations. To effectively combat future RV pandemics and epidemics, it is essential to systematically or antigenically analyze the factors driving the outbreaks and evaluate the extent to which existing therapies can control them. Equitable vaccine distribution, public health initiatives, and the development of broad-spectrum antivirals will be crucial in continuously suppressing viral replication.</p><p>In managing pandemics, it is evident that governments and the private healthcare sector must coordinate to strengthen healthcare systems. Scientists and medical professionals worldwide must conduct comprehensive studies on pandemic pathogens using genetic monitoring and sequencing to detect and track new variants, thus developing effective antivirals, vaccines, and treatments.</p><p>International epidemiological and clinical communities must collaborate to create efficient diagnostic techniques, introduce new technologies for surveillance of emerging infections, and implement strategic public health interventions to control disease transmission. To avoid drug or vaccine shortages, proactive regulatory norms, innovative production technologies, and streamlined raw material procurement processes must be established. These initiatives, coupled with global cooperation, can mitigate the risks of future pandemics.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, P.M. and S.Y.Y.; methodology, P.M. and J.M.; validation, S.Y.Y.; investigation, P.M. and J.M.; writing&#8212;original draft preparation, P.M. and J.M.; writing&#8212;review and editing, S.Y.Y.; supervision, S.Y.Y.; project administration, S.Y.Y.; and funding acquisition, S.Y.Y. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01220"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>van Doorn</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>33&#8212;Viral Respiratory Infections</article-title><source>Hunter&#8217;s Tropical Medicine and Emerging Infectious Diseases</source><edition>10th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Ryan</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Endy</surname><given-names>T.P.</given-names></name></person-group><publisher-name>Elsevier</publisher-name><publisher-loc>London, UK</publisher-loc><year>2020</year><fpage>284</fpage><lpage>288</lpage></element-citation></ref><ref id="B2-vaccines-12-01220"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mahanty</surname><given-names>S.</given-names></name></person-group><article-title>Respiratory Virus Infections: Understanding COVID-19</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>905</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.004</pub-id><pub-id pub-id-type="pmid">32497522</pub-id><pub-id pub-id-type="pmcid">PMC7237932</pub-id></element-citation></ref><ref id="B3-vaccines-12-01220"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>N.H.L.</given-names></name></person-group><article-title>Transmissibility and transmission of respiratory viruses</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>528</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00535-6</pub-id><pub-id pub-id-type="pmid">33753932</pub-id><pub-id pub-id-type="pmcid">PMC7982882</pub-id></element-citation></ref><ref id="B4-vaccines-12-01220"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Prather</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sznitman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lakdawala</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tufekci</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Marr</surname><given-names>L.C.</given-names></name></person-group><article-title>Airborne transmission of respiratory viruses</article-title><source>Science</source><year>2021</year><volume>373</volume><fpage>eabd9149</fpage><pub-id pub-id-type="doi">10.1126/science.abd9149</pub-id><pub-id pub-id-type="pmid">34446582</pub-id><pub-id pub-id-type="pmcid">PMC8721651</pub-id></element-citation></ref><ref id="B5-vaccines-12-01220"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutter</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Spronken</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Fraaij</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Herfst</surname><given-names>S.</given-names></name></person-group><article-title>Transmission routes of respiratory viruses among humans</article-title><source>Curr. Opin. Virol.</source><year>2018</year><volume>28</volume><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2018.01.001</pub-id><pub-id pub-id-type="pmid">29452994</pub-id><pub-id pub-id-type="pmcid">PMC7102683</pub-id></element-citation></ref><ref id="B6-vaccines-12-01220"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hugentobler</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Seasonality of Respiratory Viral Infections</article-title><source>Annu. Rev. Virol.</source><year>2020</year><volume>7</volume><fpage>83</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-012420-022445</pub-id><pub-id pub-id-type="pmid">32196426</pub-id></element-citation></ref><ref id="B7-vaccines-12-01220"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Viral respiratory infections in a rapidly changing climate: The need to prepare for the next pandemic</article-title><source>EBioMedicine</source><year>2023</year><volume>93</volume><elocation-id>104593</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2023.104593</pub-id><pub-id pub-id-type="pmid">37169688</pub-id><pub-id pub-id-type="pmcid">PMC10363434</pub-id></element-citation></ref><ref id="B8-vaccines-12-01220"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Schwemmle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciminski</surname><given-names>K.</given-names></name></person-group><article-title>Influenza A Viruses and Zoonotic Events&#8212;Are We Creating Our Own Reservoirs?</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>2250</elocation-id><pub-id pub-id-type="doi">10.3390/v13112250</pub-id><pub-id pub-id-type="pmid">34835056</pub-id><pub-id pub-id-type="pmcid">PMC8624301</pub-id></element-citation></ref><ref id="B9-vaccines-12-01220"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esposito</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Turku</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lehrfield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shoman</surname><given-names>A.</given-names></name></person-group><article-title>The Impact of Human Activities on Zoonotic Infection Transmissions</article-title><source>Animals</source><year>2023</year><volume>13</volume><elocation-id>1646</elocation-id><pub-id pub-id-type="doi">10.3390/ani13101646</pub-id><pub-id pub-id-type="pmid">37238075</pub-id><pub-id pub-id-type="pmcid">PMC10215220</pub-id></element-citation></ref><ref id="B10-vaccines-12-01220"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escudero-P&#233;rez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lalande</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>P.</given-names></name></person-group><article-title>Host&#8211;Pathogen Interactions Influencing Zoonotic Spillover Potential and Transmission in Humans</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>599</elocation-id><pub-id pub-id-type="doi">10.3390/v15030599</pub-id><pub-id pub-id-type="pmid">36992308</pub-id><pub-id pub-id-type="pmcid">PMC10060007</pub-id></element-citation></ref><ref id="B11-vaccines-12-01220"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jelinek</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alefishat</surname><given-names>E.</given-names></name><name name-style="western"><surname>Osman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Spence</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>J.</given-names></name><name name-style="western"><surname>Magni</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Sahibzada</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Evolution, Ecology, and Zoonotic Transmission of Betacoronaviruses: A Review</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>644414</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.644414</pub-id><pub-id pub-id-type="pmid">34095271</pub-id><pub-id pub-id-type="pmcid">PMC8173069</pub-id></element-citation></ref><ref id="B12-vaccines-12-01220"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelwhab</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Mettenleiter</surname><given-names>T.C.</given-names></name></person-group><article-title>Zoonotic Animal Influenza Virus and Potential Mixing Vessel Hosts</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>980</elocation-id><pub-id pub-id-type="doi">10.3390/v15040980</pub-id><pub-id pub-id-type="pmid">37112960</pub-id><pub-id pub-id-type="pmcid">PMC10145017</pub-id></element-citation></ref><ref id="B13-vaccines-12-01220"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sooksawasdi Na Ayudhya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name></person-group><article-title>Reverse Zoonosis of COVID-19: Lessons From the 2009 Influenza Pandemic</article-title><source>Vet. Pathol.</source><year>2021</year><volume>58</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1177/0300985820979843</pub-id><pub-id pub-id-type="pmid">33295843</pub-id><pub-id pub-id-type="pmcid">PMC7961641</pub-id></element-citation></ref><ref id="B14-vaccines-12-01220"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Aravena</surname><given-names>M.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lunn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>A.</given-names></name><name name-style="western"><surname>Snedden</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Yinda</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Port</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>Ecology, evolution and spillover of coronaviruses from bats</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>299</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00652-2</pub-id><pub-id pub-id-type="pmid">34799704</pub-id><pub-id pub-id-type="pmcid">PMC8603903</pub-id></element-citation></ref><ref id="B15-vaccines-12-01220"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dharmarajan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>I.</given-names></name></person-group><article-title>Evolution of pathogen tolerance and emerging infections: A missing experimental paradigm</article-title><source>Elife</source><year>2021</year><volume>10</volume><fpage>e68874</fpage><pub-id pub-id-type="doi">10.7554/eLife.68874</pub-id><pub-id pub-id-type="pmid">34544548</pub-id><pub-id pub-id-type="pmcid">PMC8455132</pub-id></element-citation></ref><ref id="B16-vaccines-12-01220"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuse</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oshitani</surname><given-names>H.</given-names></name></person-group><article-title>Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>583252</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.583252</pub-id><pub-id pub-id-type="pmid">33042101</pub-id><pub-id pub-id-type="pmcid">PMC7530166</pub-id></element-citation></ref><ref id="B17-vaccines-12-01220"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihaescu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chifiriuc</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Iliescu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vrancianu</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Ditu</surname><given-names>L.-M.</given-names></name><name name-style="western"><surname>Marutescu</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Grigore</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berte&#537;teanu</surname><given-names>&#536;.</given-names></name><name name-style="western"><surname>Constantin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gradisteanu Pircalabioru</surname><given-names>G.</given-names></name></person-group><article-title>SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>1468</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8101468</pub-id><pub-id pub-id-type="pmid">32987852</pub-id><pub-id pub-id-type="pmcid">PMC7600570</pub-id></element-citation></ref><ref id="B18-vaccines-12-01220"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalil</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.G.</given-names></name></person-group><article-title>Influenza virus-related critical illness: Pathophysiology and epidemiology</article-title><source>Crit. Care</source><year>2019</year><volume>23</volume><fpage>258</fpage><pub-id pub-id-type="doi">10.1186/s13054-019-2539-x</pub-id><pub-id pub-id-type="pmid">31324202</pub-id><pub-id pub-id-type="pmcid">PMC6642581</pub-id></element-citation></ref><ref id="B19-vaccines-12-01220"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhadoria</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name></person-group><article-title>Viral Pandemics in the Past Two Decades: An Overview</article-title><source>J. Fam. Med. Prim. Care</source><year>2021</year><volume>10</volume><fpage>2745</fpage><lpage>2750</lpage><pub-id pub-id-type="doi">10.4103/jfmpc.jfmpc_2071_20</pub-id><pub-id pub-id-type="pmcid">PMC8483091</pub-id><pub-id pub-id-type="pmid">34660399</pub-id></element-citation></ref><ref id="B20-vaccines-12-01220"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makarov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Riabova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ekins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pluzhnikov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chepur</surname><given-names>S.</given-names></name></person-group><article-title>The past, present and future of RNA respiratory viruses: Influenza and coronaviruses</article-title><source>Pathog. Dis.</source><year>2020</year><volume>78</volume><fpage>ftaa046</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftaa046</pub-id><pub-id pub-id-type="pmid">32860686</pub-id><pub-id pub-id-type="pmcid">PMC7499567</pub-id></element-citation></ref><ref id="B21-vaccines-12-01220"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;imi&#269;i&#263;</surname><given-names>P.</given-names></name><name name-style="western"><surname>&#381;idovec-Lepej</surname><given-names>S.</given-names></name></person-group><article-title>A Glimpse on the Evolution of RNA Viruses: Implications and Lessons from SARS-CoV-2</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/v15010001</pub-id><pub-id pub-id-type="pmcid">PMC9866536</pub-id><pub-id pub-id-type="pmid">36680042</pub-id></element-citation></ref><ref id="B22-vaccines-12-01220"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name></person-group><article-title>A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>6369</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24076369</pub-id><pub-id pub-id-type="pmid">37047339</pub-id><pub-id pub-id-type="pmcid">PMC10094131</pub-id></element-citation></ref><ref id="B23-vaccines-12-01220"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Behl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohagaonkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gambhir</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Butola</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name></person-group><article-title>Threat, challenges, and preparedness for future pandemics: A descriptive review of phylogenetic analysis based predictions</article-title><source>Infect. Genet. Evol.</source><year>2022</year><volume>98</volume><fpage>105217</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2022.105217</pub-id><pub-id pub-id-type="pmid">35065303</pub-id></element-citation></ref><ref id="B24-vaccines-12-01220"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovanetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Branda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cella</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bazzani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Slavov</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Benvenuto</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>D.</given-names></name><name name-style="western"><surname>Casu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e29012</fpage><pub-id pub-id-type="doi">10.1002/jmv.29012</pub-id><pub-id pub-id-type="pmid">37548148</pub-id></element-citation></ref><ref id="B25-vaccines-12-01220"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Kackos</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>The evolution and future of influenza pandemic preparedness</article-title><source>Exp. Mol. Med.</source><year>2021</year><volume>53</volume><fpage>737</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1038/s12276-021-00603-0</pub-id><pub-id pub-id-type="pmid">33953324</pub-id><pub-id pub-id-type="pmcid">PMC8099712</pub-id></element-citation></ref><ref id="B26-vaccines-12-01220"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.J.D.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kedzierska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Treanor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><etal/></person-group><article-title>Influenza</article-title><source>Nat. Rev. Dis. Primers</source><year>2018</year><volume>4</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1038/s41572-018-0002-y</pub-id><pub-id pub-id-type="pmid">29955068</pub-id><pub-id pub-id-type="pmcid">PMC7097467</pub-id></element-citation></ref><ref id="B27-vaccines-12-01220"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCaughey</surname><given-names>C.</given-names></name></person-group><article-title>Influenza: A virus of our times</article-title><source>Ulster Med. J.</source><year>2010</year><volume>79</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">21116418</pub-id><pub-id pub-id-type="pmcid">PMC2993133</pub-id></element-citation></ref><ref id="B28-vaccines-12-01220"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsobaie</surname><given-names>S.</given-names></name></person-group><article-title>Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review</article-title><source>Infect. Drug Resist.</source><year>2021</year><volume>14</volume><fpage>2259</fpage><lpage>2268</lpage><pub-id pub-id-type="doi">10.2147/IDR.S306441</pub-id><pub-id pub-id-type="pmid">34163190</pub-id><pub-id pub-id-type="pmcid">PMC8215902</pub-id></element-citation></ref><ref id="B29-vaccines-12-01220"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaye</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Cornett</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Brondeel</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>Z.I.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Erwin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Charipova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gress</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Urits</surname><given-names>I.</given-names></name><name name-style="western"><surname>Urman</surname><given-names>R.D.</given-names></name><etal/></person-group><article-title>Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment</article-title><source>Best Pract. Res. Clin. Anaesthesiol.</source><year>2021</year><volume>35</volume><fpage>269</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2020.12.003</pub-id><pub-id pub-id-type="pmid">34511219</pub-id><pub-id pub-id-type="pmcid">PMC7723419</pub-id></element-citation></ref><ref id="B30-vaccines-12-01220"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moghadami</surname><given-names>M.</given-names></name></person-group><article-title>A Narrative Review of Influenza: A Seasonal and Pandemic Disease</article-title><source>Iran. J. Med. Sci.</source><year>2017</year><volume>42</volume><fpage>2</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">28293045</pub-id><pub-id pub-id-type="pmcid">PMC5337761</pub-id></element-citation></ref><ref id="B31-vaccines-12-01220"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubenberger</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Morens</surname><given-names>D.M.</given-names></name></person-group><article-title>Influenza: The once and future pandemic</article-title><source>Public Health Rep.</source><year>2010</year><volume>125</volume><issue>(Suppl. 3)</issue><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1177/00333549101250S305</pub-id><pub-id pub-id-type="pmcid">PMC2862331</pub-id><pub-id pub-id-type="pmid">20568566</pub-id></element-citation></ref><ref id="B32-vaccines-12-01220"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kroneman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wiegers</surname><given-names>T.</given-names></name><name name-style="western"><surname>El Guerche-S&#233;blain</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paget</surname><given-names>J.</given-names></name></person-group><article-title>Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: A systematic literature review</article-title><source>Influenza Other Respir. Viruses</source><year>2018</year><volume>12</volume><fpage>780</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1111/irv.12575</pub-id><pub-id pub-id-type="pmid">29858537</pub-id><pub-id pub-id-type="pmcid">PMC6185883</pub-id></element-citation></ref><ref id="B33-vaccines-12-01220"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mettelman</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.G.</given-names></name></person-group><article-title>Human Susceptibility to Influenza Infection and Severe Disease</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2021</year><volume>11</volume><fpage>a038711</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a038711</pub-id><pub-id pub-id-type="pmid">31964647</pub-id><pub-id pub-id-type="pmcid">PMC8091954</pub-id></element-citation></ref><ref id="B34-vaccines-12-01220"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>T.K.W.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L.L.M.</given-names></name></person-group><article-title>Biology of Influenza A Virus</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2007</year><volume>1102</volume><fpage>1</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1196/annals.1408.001</pub-id><pub-id pub-id-type="pmid">17470908</pub-id></element-citation></ref><ref id="B35-vaccines-12-01220"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Revol</surname><given-names>R.</given-names></name><name name-style="western"><surname>&#214;stbye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>R.</given-names></name></person-group><article-title>Influenza A Virus Cell Entry, Replication, Virion Assembly and Movement</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>1581</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.01581</pub-id><pub-id pub-id-type="pmid">30079062</pub-id><pub-id pub-id-type="pmcid">PMC6062596</pub-id></element-citation></ref><ref id="B36-vaccines-12-01220"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Goraya</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.L.</given-names></name></person-group><article-title>Evolution of Influenza A Virus by Mutation and Re-Assortment</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1650</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18081650</pub-id><pub-id pub-id-type="pmid">28783091</pub-id><pub-id pub-id-type="pmcid">PMC5578040</pub-id></element-citation></ref><ref id="B37-vaccines-12-01220"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostafa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdelwhab</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Mettenleiter</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Pleschka</surname><given-names>S.</given-names></name></person-group><article-title>Zoonotic Potential of Influenza A Viruses: A Comprehensive Overview</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>497</elocation-id><pub-id pub-id-type="doi">10.3390/v10090497</pub-id><pub-id pub-id-type="pmid">30217093</pub-id><pub-id pub-id-type="pmcid">PMC6165440</pub-id></element-citation></ref><ref id="B38-vaccines-12-01220"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Influenza Virus: Dealing with a Drifting and Shifting Pathogen</article-title><source>Viral Immunol.</source><year>2018</year><volume>31</volume><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1089/vim.2017.0141</pub-id><pub-id pub-id-type="pmid">29373086</pub-id></element-citation></ref><ref id="B39-vaccines-12-01220"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#8217;kovski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kratzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thiel</surname><given-names>V.</given-names></name></person-group><article-title>Coronavirus biology and replication: Implications for SARS-CoV-2</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>155</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00468-6</pub-id><pub-id pub-id-type="pmid">33116300</pub-id><pub-id pub-id-type="pmcid">PMC7592455</pub-id></element-citation></ref><ref id="B40-vaccines-12-01220"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singhal</surname><given-names>T.</given-names></name></person-group><article-title>The Emergence of Omicron: Challenging Times Are Here Again!</article-title><source>Indian J. Pediatr.</source><year>2022</year><volume>89</volume><fpage>490</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1007/s12098-022-04077-4</pub-id><pub-id pub-id-type="pmid">35025038</pub-id><pub-id pub-id-type="pmcid">PMC8756165</pub-id></element-citation></ref><ref id="B41-vaccines-12-01220"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li&#232;vre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Laurenson-Schafer</surname><given-names>H.</given-names></name><name name-style="western"><surname>de Barros</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jinnai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Formigo</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perrocheau</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The World Health Organization COVID-19 surveillance database</article-title><source>Int. J. Equity Health</source><year>2022</year><volume>21</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1186/s12939-022-01767-5</pub-id><pub-id pub-id-type="pmid">36419127</pub-id><pub-id pub-id-type="pmcid">PMC9685131</pub-id></element-citation></ref><ref id="B42-vaccines-12-01220"><label>42.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akbar Samad</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Vaqar</surname><given-names>S.</given-names></name></person-group><article-title>Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19)</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing LLC.</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">34033342</pub-id></element-citation></ref><ref id="B43-vaccines-12-01220"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavda</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Vaghasiya</surname><given-names>D.D.</given-names></name></person-group><article-title>SARS-CoV-2 variants and vulnerability at the global level</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>2986</fpage><lpage>3005</lpage><pub-id pub-id-type="doi">10.1002/jmv.27717</pub-id><pub-id pub-id-type="pmid">35277864</pub-id><pub-id pub-id-type="pmcid">PMC9088647</pub-id></element-citation></ref><ref id="B44-vaccines-12-01220"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiergens</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Nitsche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></element-citation></ref><ref id="B45-vaccines-12-01220"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bestle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heindl</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Limburg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Lam van</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pilgram</surname><given-names>O.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Hardes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dolnik</surname><given-names>O.</given-names></name><etal/></person-group><article-title>TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells</article-title><source>Life Sci. Alliance</source><year>2020</year><volume>3</volume><fpage>e202000786</fpage><pub-id pub-id-type="doi">10.26508/lsa.202000786</pub-id><pub-id pub-id-type="pmid">32703818</pub-id><pub-id pub-id-type="pmcid">PMC7383062</pub-id></element-citation></ref><ref id="B46-vaccines-12-01220"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>P.</given-names></name><name name-style="western"><surname>Somogyv&#225;ri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Virok</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Noseda</surname><given-names>M.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>G.R.</given-names></name></person-group><article-title>Decoding COVID-19 with the SARS-CoV-2 Genome</article-title><source>Curr. Genet. Med. Rep.</source><year>2021</year><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s40142-020-00197-5</pub-id><pub-id pub-id-type="pmid">33457109</pub-id><pub-id pub-id-type="pmcid">PMC7794078</pub-id></element-citation></ref><ref id="B47-vaccines-12-01220"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rastogi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.K.</given-names></name></person-group><article-title>SARS coronavirus 2: From genome to infectome</article-title><source>Respir. Res.</source><year>2020</year><volume>21</volume><fpage>318</fpage><pub-id pub-id-type="doi">10.1186/s12931-020-01581-z</pub-id><pub-id pub-id-type="pmid">33261606</pub-id><pub-id pub-id-type="pmcid">PMC7706175</pub-id></element-citation></ref><ref id="B48-vaccines-12-01220"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brant</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Majerciak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.-M.</given-names></name></person-group><article-title>SARS-CoV-2: From its discovery to genome structure, transcription, and replication</article-title><source>Cell Biosci.</source><year>2021</year><volume>11</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.1186/s13578-021-00643-z</pub-id><pub-id pub-id-type="pmid">34281608</pub-id><pub-id pub-id-type="pmcid">PMC8287290</pub-id></element-citation></ref><ref id="B49-vaccines-12-01220"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Maghsoudloo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics</article-title><source>Drug Discov. Today</source><year>2024</year><volume>29</volume><fpage>104026</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2024.104026</pub-id><pub-id pub-id-type="pmid">38762086</pub-id></element-citation></ref><ref id="B50-vaccines-12-01220"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Animal models for COVID-19: Advances, gaps and perspectives</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><volume>7</volume><fpage>220</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01087-8</pub-id><pub-id pub-id-type="pmid">35798699</pub-id><pub-id pub-id-type="pmcid">PMC9261903</pub-id></element-citation></ref><ref id="B51-vaccines-12-01220"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borkotoky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hazarika</surname><given-names>Z.</given-names></name></person-group><article-title>Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): A structural perspective</article-title><source>Mol. Biol. Rep.</source><year>2023</year><volume>50</volume><fpage>2713</fpage><lpage>2721</lpage><pub-id pub-id-type="doi">10.1007/s11033-022-08193-4</pub-id><pub-id pub-id-type="pmid">36562937</pub-id><pub-id pub-id-type="pmcid">PMC9786537</pub-id></element-citation></ref><ref id="B52-vaccines-12-01220"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>N.Q.</given-names></name><name name-style="western"><surname>Sikora</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.S.</given-names></name></person-group><article-title>Interaction of SARS-CoV-2 with host cells and antibodies: Experiment and simulation</article-title><source>Chem. Soc. Rev.</source><year>2023</year><volume>52</volume><fpage>6497</fpage><lpage>6553</lpage><pub-id pub-id-type="doi">10.1039/D1CS01170G</pub-id><pub-id pub-id-type="pmid">37650302</pub-id></element-citation></ref><ref id="B53-vaccines-12-01220"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bejoy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Manzoor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davoodi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Battaile</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nikolaienko</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Brelidze</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Gychka</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>Effects of spike proteins on angiotensin converting enzyme 2 (ACE2)</article-title><source>Arch. Biochem. Biophys.</source><year>2023</year><volume>748</volume><elocation-id>109769</elocation-id><pub-id pub-id-type="doi">10.1016/j.abb.2023.109769</pub-id><pub-id pub-id-type="pmid">37769892</pub-id><pub-id pub-id-type="pmcid">PMC10615800</pub-id></element-citation></ref><ref id="B54-vaccines-12-01220"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barthe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hertereau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lamghari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Osman-Ponchet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Braud</surname><given-names>V.M.</given-names></name></person-group><article-title>Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>6253</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24076253</pub-id><pub-id pub-id-type="pmid">37047226</pub-id><pub-id pub-id-type="pmcid">PMC10094153</pub-id></element-citation></ref><ref id="B55-vaccines-12-01220"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa Dos Santos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ximenes Rabelo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mattana Sebben</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Souza Carneiro</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Bosco Lopes Botelho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cardoso Neto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nogueira Barbosa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monteiro de Carvalho</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pontes</surname><given-names>G.S.</given-names></name></person-group><article-title>Persistence of SARS-CoV-2 Antigens in the Nasal Mucosa of Eight Patients with Inflammatory Rhinopathy for over 80 Days following Mild COVID-19 Diagnosis</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>899</elocation-id><pub-id pub-id-type="doi">10.3390/v15040899</pub-id><pub-id pub-id-type="pmid">37112879</pub-id><pub-id pub-id-type="pmcid">PMC10143909</pub-id></element-citation></ref><ref id="B56-vaccines-12-01220"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>K.P.Y.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>C.H.T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.C.W.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.M.T.</given-names></name><name name-style="western"><surname>Kuok</surname><given-names>D.I.T.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: An analysis in ex-vivo and in-vitro cultures</article-title><source>Lancet Respir. Med.</source><year>2020</year><volume>8</volume><fpage>687</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30193-4</pub-id><pub-id pub-id-type="pmid">32386571</pub-id><pub-id pub-id-type="pmcid">PMC7252187</pub-id></element-citation></ref><ref id="B57-vaccines-12-01220"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhont</surname><given-names>S.</given-names></name><name name-style="western"><surname>Derom</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Braeckel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Depuydt</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name></person-group><article-title>The pathophysiology of &#8216;happy&#8217; hypoxemia in COVID-19</article-title><source>Respir. Res.</source><year>2020</year><volume>21</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1186/s12931-020-01462-5</pub-id><pub-id pub-id-type="pmid">32723327</pub-id><pub-id pub-id-type="pmcid">PMC7385717</pub-id></element-citation></ref><ref id="B58-vaccines-12-01220"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cilloniz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luna</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hurtado</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Marcos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.</given-names></name></person-group><article-title>Respiratory viruses: Their importance and lessons learned from COVID-19</article-title><source>Eur. Respir. Rev.</source><year>2022</year><volume>31</volume><fpage>220051</fpage><pub-id pub-id-type="doi">10.1183/16000617.0051-2022</pub-id><pub-id pub-id-type="pmid">36261158</pub-id><pub-id pub-id-type="pmcid">PMC9724808</pub-id></element-citation></ref><ref id="B59-vaccines-12-01220"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memoli</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Athota</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czajkowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bristol</surname><given-names>T.</given-names></name><name name-style="western"><surname>Proudfoot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hagey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Voell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fiorentino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ademposi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The Natural History of Influenza Infection in the Severely Immunocompromised vs Nonimmunocompromised Hosts</article-title><source>Clin. Infect. Dis.</source><year>2013</year><volume>58</volume><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1093/cid/cit725</pub-id><pub-id pub-id-type="pmid">24186906</pub-id><pub-id pub-id-type="pmcid">PMC3871797</pub-id></element-citation></ref><ref id="B60-vaccines-12-01220"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Spillane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Comber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cardwell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>P.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Teljeur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Gascun</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>The duration of infectiousness of individuals infected with SARS-CoV-2</article-title><source>J. Infect.</source><year>2020</year><volume>81</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.10.009</pub-id><pub-id pub-id-type="pmid">33049331</pub-id><pub-id pub-id-type="pmcid">PMC7547320</pub-id></element-citation></ref><ref id="B61-vaccines-12-01220"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>H.-E.</given-names></name><name name-style="western"><surname>Rha</surname><given-names>M.-S.</given-names></name></person-group><article-title>Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract</article-title><source>Pathogens</source><year>2024</year><volume>13</volume><elocation-id>113</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens13020113</pub-id><pub-id pub-id-type="pmid">38392851</pub-id><pub-id pub-id-type="pmcid">PMC10892713</pub-id></element-citation></ref><ref id="B62-vaccines-12-01220"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed-Hassan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sisson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Wijewantha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Funderburg</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>D.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Demberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liyanage</surname><given-names>N.P.M.</given-names></name></person-group><article-title>Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>1979</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01979</pub-id><pub-id pub-id-type="pmid">32973803</pub-id><pub-id pub-id-type="pmcid">PMC7468245</pub-id></element-citation></ref><ref id="B63-vaccines-12-01220"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crotta</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>Pathogenic potential of interferon &#945;&#946; in acute influenza infection</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3864</fpage><pub-id pub-id-type="doi">10.1038/ncomms4864</pub-id><pub-id pub-id-type="pmid">24844667</pub-id><pub-id pub-id-type="pmcid">PMC4033792</pub-id></element-citation></ref><ref id="B64-vaccines-12-01220"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westphalen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gusarova</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>J.</given-names></name></person-group><article-title>Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity</article-title><source>Nature</source><year>2014</year><volume>506</volume><fpage>503</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nature12902</pub-id><pub-id pub-id-type="pmid">24463523</pub-id><pub-id pub-id-type="pmcid">PMC4117212</pub-id></element-citation></ref><ref id="B65-vaccines-12-01220"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Angel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vuckovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>D.N.J.</given-names></name></person-group><article-title>The role of dendritic cells in the innate immune system</article-title><source>Microbes Infect.</source><year>2000</year><volume>2</volume><fpage>257</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(00)00302-6</pub-id><pub-id pub-id-type="pmid">10758402</pub-id></element-citation></ref><ref id="B66-vaccines-12-01220"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goraya</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Maarouf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.-L.</given-names></name></person-group><article-title>Host Immune Response to Influenza A Virus Infection</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>320</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00320</pub-id><pub-id pub-id-type="pmid">29556226</pub-id><pub-id pub-id-type="pmcid">PMC5845129</pub-id></element-citation></ref><ref id="B67-vaccines-12-01220"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ikegawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name></person-group><article-title>Antigen Presentation in the Lung</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>860915</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.860915</pub-id><pub-id pub-id-type="pmid">35615351</pub-id><pub-id pub-id-type="pmcid">PMC9124800</pub-id></element-citation></ref><ref id="B68-vaccines-12-01220"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yunis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Short</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name></person-group><article-title>Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation</article-title><source>Trends Microbiol.</source><year>2023</year><volume>31</volume><fpage>644</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2022.12.008</pub-id><pub-id pub-id-type="pmid">36635162</pub-id><pub-id pub-id-type="pmcid">PMC9829516</pub-id></element-citation></ref><ref id="B69-vaccines-12-01220"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braciale</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.S.</given-names></name></person-group><article-title>Regulating the adaptive immune response to respiratory virus infection</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nri3166</pub-id><pub-id pub-id-type="pmid">22402670</pub-id><pub-id pub-id-type="pmcid">PMC3364025</pub-id></element-citation></ref><ref id="B70-vaccines-12-01220"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nicols</surname><given-names>A.</given-names></name><name name-style="western"><surname>Turtle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Dunachie</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Klenerman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Payne</surname><given-names>R.P.</given-names></name></person-group><article-title>T cell immune memory after covid-19 and vaccination</article-title><source>BMJ Med.</source><year>2023</year><volume>2</volume><fpage>e000468</fpage><pub-id pub-id-type="doi">10.1136/bmjmed-2022-000468</pub-id><pub-id pub-id-type="pmcid">PMC10668147</pub-id><pub-id pub-id-type="pmid">38027416</pub-id></element-citation></ref><ref id="B71-vaccines-12-01220"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murdaca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paladin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tonacci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Isola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allegra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gangemi</surname><given-names>S.</given-names></name></person-group><article-title>The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic</article-title><source>Biomedicines</source><year>2021</year><volume>9</volume><elocation-id>1688</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines9111688</pub-id><pub-id pub-id-type="pmid">34829918</pub-id><pub-id pub-id-type="pmcid">PMC8615478</pub-id></element-citation></ref><ref id="B72-vaccines-12-01220"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>589095</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.589095</pub-id><pub-id pub-id-type="pmid">33995341</pub-id><pub-id pub-id-type="pmcid">PMC8115911</pub-id></element-citation></ref><ref id="B73-vaccines-12-01220"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name></person-group><article-title>SARS-CoV-2 pathogenesis</article-title><source>Nat. Rev. Microbiol.</source><year>2022</year><volume>20</volume><fpage>270</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00713-0</pub-id><pub-id pub-id-type="pmid">35354968</pub-id></element-citation></ref><ref id="B74-vaccines-12-01220"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Holbrook</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Gamble</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harcourt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Thornburg</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>1564</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id><pub-id pub-id-type="pmid">32182409</pub-id><pub-id pub-id-type="pmcid">PMC7121658</pub-id></element-citation></ref><ref id="B75-vaccines-12-01220"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teunis</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Brienen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kretzschmar</surname><given-names>M.E.</given-names></name></person-group><article-title>High infectivity and pathogenicity of influenza A virus via aerosol and droplet transmission</article-title><source>Epidemics</source><year>2010</year><volume>2</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.epidem.2010.10.001</pub-id><pub-id pub-id-type="pmid">21352792</pub-id></element-citation></ref><ref id="B76-vaccines-12-01220"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name></person-group><article-title>Transmission and infection risk of COVID-19 when people coughing in an elevator</article-title><source>Build. Environ.</source><year>2023</year><volume>238</volume><fpage>110343</fpage><pub-id pub-id-type="doi">10.1016/j.buildenv.2023.110343</pub-id><pub-id pub-id-type="pmid">37143581</pub-id><pub-id pub-id-type="pmcid">PMC10122966</pub-id></element-citation></ref><ref id="B77-vaccines-12-01220"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>R.</given-names></name></person-group><article-title>Probability of COVID-19 infection by cough of a normal person and a super-spreader</article-title><source>Phys. Fluids (1994)</source><year>2021</year><volume>33</volume><fpage>031704</fpage><pub-id pub-id-type="doi">10.1063/5.0041596</pub-id><pub-id pub-id-type="pmid">33746492</pub-id><pub-id pub-id-type="pmcid">PMC7976050</pub-id></element-citation></ref><ref id="B78-vaccines-12-01220"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thangavel</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>N.M.</given-names></name></person-group><article-title>Animal models for influenza virus pathogenesis, transmission, and immunology</article-title><source>J. Immunol. Methods</source><year>2014</year><volume>410</volume><fpage>60</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.03.023</pub-id><pub-id pub-id-type="pmid">24709389</pub-id><pub-id pub-id-type="pmcid">PMC4163064</pub-id></element-citation></ref><ref id="B79-vaccines-12-01220"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doorn</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>C.M.A.</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>N.K.H.</given-names></name></person-group><article-title>Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission</article-title><source>Aliment. Pharmacol. Ther.</source><year>2020</year><volume>52</volume><fpage>1276</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1111/apt.16036</pub-id><pub-id pub-id-type="pmid">32852082</pub-id><pub-id pub-id-type="pmcid">PMC7461227</pub-id></element-citation></ref><ref id="B80-vaccines-12-01220"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name></person-group><article-title>Potential intestinal infection and faecal&#8211;oral transmission of SARS-CoV-2</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2021</year><volume>18</volume><fpage>269</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00416-6</pub-id><pub-id pub-id-type="pmid">33589829</pub-id><pub-id pub-id-type="pmcid">PMC7883337</pub-id></element-citation></ref><ref id="B81-vaccines-12-01220"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Khatib</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Al Maslamani</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Al Thani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Pathan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name></person-group><article-title>Molecular and biological characterization of influenza A viruses isolated from human fecal samples</article-title><source>Infect. Genet. Evol.</source><year>2021</year><volume>93</volume><fpage>104972</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.104972</pub-id><pub-id pub-id-type="pmid">34153546</pub-id></element-citation></ref><ref id="B82-vaccines-12-01220"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutti-Sridharan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vegunta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vegunta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Rokkam</surname><given-names>V.R.P.</given-names></name></person-group><article-title>SARS-CoV2 in Different Body Fluids, Risks of Transmission, and Preventing COVID-19: A Comprehensive Evidence-Based Review</article-title><source>Int. J. Prev. Med.</source><year>2020</year><volume>11</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.4103/ijpvm.IJPVM_255_20</pub-id><pub-id pub-id-type="pmid">33042494</pub-id><pub-id pub-id-type="pmcid">PMC7518359</pub-id></element-citation></ref><ref id="B83-vaccines-12-01220"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name></person-group><article-title>Influenza A (H1N1)</article-title><source>Radiol. Infect. Dis.</source><year>2015</year><volume>1</volume><fpage>465</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1007/978-94-017-9882-2_22</pub-id></element-citation></ref><ref id="B84-vaccines-12-01220"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Near</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young-Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>C.M.</given-names></name></person-group><article-title>Burden of influenza hospitalization among high-risk groups in the United States</article-title><source>BMC Health Serv. Res.</source><year>2022</year><volume>22</volume><elocation-id>1209</elocation-id><pub-id pub-id-type="doi">10.1186/s12913-022-08586-y</pub-id><pub-id pub-id-type="pmid">36171601</pub-id><pub-id pub-id-type="pmcid">PMC9520810</pub-id></element-citation></ref><ref id="B85-vaccines-12-01220"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nalla</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Malim</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Ghatage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mukarram</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pawar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parihar</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Association of COVID-19 with Comorbidities: An Update</article-title><source>ACS Pharmacol. Transl. Sci.</source><year>2023</year><volume>6</volume><fpage>334</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.2c00181</pub-id><pub-id pub-id-type="pmid">36923110</pub-id><pub-id pub-id-type="pmcid">PMC10000013</pub-id></element-citation></ref><ref id="B86-vaccines-12-01220"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadela</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Megha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhagat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chavda</surname><given-names>V.P.</given-names></name></person-group><article-title>A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities</article-title><source>Biologics</source><year>2023</year><volume>3</volume><fpage>138</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.3390/biologics3020008</pub-id></element-citation></ref><ref id="B87-vaccines-12-01220"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Javanian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghebrehewet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koppolu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vasigala</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ebrahimpour</surname><given-names>S.</given-names></name></person-group><article-title>A brief review of influenza virus infection</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>4638</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.1002/jmv.26990</pub-id><pub-id pub-id-type="pmid">33792930</pub-id></element-citation></ref><ref id="B88-vaccines-12-01220"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Serres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rouleau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hamelin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Quach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Skowronski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Flamand</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boulianne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bourgault</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Contagious period for pandemic (H1N1) 2009</article-title><source>Emerg. Infect. Dis.</source><year>2010</year><volume>16</volume><fpage>783</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.3201/eid1605.091894</pub-id><pub-id pub-id-type="pmid">20409367</pub-id><pub-id pub-id-type="pmcid">PMC2954014</pub-id></element-citation></ref><ref id="B89-vaccines-12-01220"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Grantz</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Meredith</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Azman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Reich</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Lessler</surname><given-names>J.</given-names></name></person-group><article-title>The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application</article-title><source>Ann. Intern. Med.</source><year>2020</year><volume>172</volume><fpage>577</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.7326/M20-0504</pub-id><pub-id pub-id-type="pmid">32150748</pub-id><pub-id pub-id-type="pmcid">PMC7081172</pub-id></element-citation></ref><ref id="B90-vaccines-12-01220"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radhi</surname><given-names>A.S.</given-names></name></person-group><article-title>Uncommon Presentation of COVID-19 With Long Incubation Period and Only Gastrointestinal Symptoms in a Fully Vaccinated Patient: Is There a Relation?</article-title><source>Cureus</source><year>2021</year><volume>13</volume><fpage>e16028</fpage><pub-id pub-id-type="doi">10.7759/cureus.16028</pub-id><pub-id pub-id-type="pmid">34336515</pub-id><pub-id pub-id-type="pmcid">PMC8320968</pub-id></element-citation></ref><ref id="B91-vaccines-12-01220"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taubenberger</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Morens</surname><given-names>D.M.</given-names></name></person-group><article-title>The 1918 Influenza Pandemic and Its Legacy</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2020</year><volume>10</volume><fpage>a038695</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a038695</pub-id><pub-id pub-id-type="pmid">31871232</pub-id><pub-id pub-id-type="pmcid">PMC7528857</pub-id></element-citation></ref><ref id="B92-vaccines-12-01220"><label>92.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Worldometer</surname><given-names>D.</given-names></name></person-group><article-title>COVID-19 Coronavirus Pandemic. World Health Organization</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.worldometers.info/coronavirus/" ext-link-type="uri">https://www.worldometers.info/coronavirus/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-24">(accessed on 24 October 2024)</date-in-citation></element-citation></ref><ref id="B93-vaccines-12-01220"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gries</surname><given-names>T.</given-names></name><name name-style="western"><surname>Redlin</surname><given-names>M.</given-names></name></person-group><article-title>The effectiveness of vaccination, testing, and lockdown strategies against COVID-19</article-title><source>Int. J. Health Econ. Manag.</source><year>2023</year><volume>23</volume><fpage>585</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1007/s10754-023-09352-1</pub-id><pub-id pub-id-type="pmid">37103662</pub-id><pub-id pub-id-type="pmcid">PMC10134731</pub-id></element-citation></ref><ref id="B94-vaccines-12-01220"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flerlage</surname><given-names>T.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Meliopoulos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Schultz-Cherry</surname><given-names>S.</given-names></name></person-group><article-title>Influenza virus and SARS-CoV-2: Pathogenesis and host responses in the respiratory tract</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>425</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/s41579-021-00542-7</pub-id><pub-id pub-id-type="pmid">33824495</pub-id><pub-id pub-id-type="pmcid">PMC8023351</pub-id></element-citation></ref><ref id="B95-vaccines-12-01220"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>R.d.C.</given-names></name><name name-style="western"><surname>Masters</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Carrico</surname><given-names>R.</given-names></name></person-group><article-title>Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice</article-title><source>Mayo Clin. Proc. Innov. Qual. Outcomes</source><year>2021</year><volume>5</volume><fpage>974</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1016/j.mayocpiqo.2021.07.005</pub-id><pub-id pub-id-type="pmid">34414356</pub-id><pub-id pub-id-type="pmcid">PMC8363430</pub-id></element-citation></ref><ref id="B96-vaccines-12-01220"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frediansyah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sharun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harapan</surname><given-names>H.</given-names></name></person-group><article-title>Antivirals for COVID-19: A critical review</article-title><source>Clin. Epidemiol. Glob. Health</source><year>2021</year><volume>9</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.cegh.2020.07.006</pub-id><pub-id pub-id-type="pmid">33521390</pub-id><pub-id pub-id-type="pmcid">PMC7831805</pub-id></element-citation></ref><ref id="B97-vaccines-12-01220"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>P.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Govorkova</surname><given-names>E.A.</given-names></name></person-group><article-title>Influenza antivirals and their role in pandemic preparedness</article-title><source>Antivir. Res.</source><year>2023</year><volume>210</volume><fpage>105499</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2022.105499</pub-id><pub-id pub-id-type="pmid">36567025</pub-id><pub-id pub-id-type="pmcid">PMC9852030</pub-id></element-citation></ref><ref id="B98-vaccines-12-01220"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Itzstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Pegg</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Dyason</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Phan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smythe</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>White</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>Rational design of potent sialidase-based inhibitors of influenza virus replication</article-title><source>Nature</source><year>1993</year><volume>363</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/363418a0</pub-id><pub-id pub-id-type="pmid">8502295</pub-id></element-citation></ref><ref id="B99-vaccines-12-01220"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#346;wierczy&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirowska-Guzel</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pindelska</surname><given-names>E.</given-names></name></person-group><article-title>Antiviral Drugs in Influenza</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>3018</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19053018</pub-id><pub-id pub-id-type="pmid">35270708</pub-id><pub-id pub-id-type="pmcid">PMC8910682</pub-id></element-citation></ref><ref id="B100-vaccines-12-01220"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Sodhi</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Bali</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Shree</surname><given-names>P.</given-names></name></person-group><article-title>Influenza A virus and its antiviral drug treatment options</article-title><source>Med. Microecol.</source><year>2023</year><volume>16</volume><fpage>100083</fpage><pub-id pub-id-type="doi">10.1016/j.medmic.2023.100083</pub-id></element-citation></ref><ref id="B101-vaccines-12-01220"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>B.E.</given-names></name></person-group><article-title>Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations</article-title><source>J. Antimicrob. Chemother.</source><year>2010</year><volume>65</volume><issue>(Suppl. 2)</issue><fpage>ii5</fpage><lpage>ii10</lpage><pub-id pub-id-type="doi">10.1093/jac/dkq015</pub-id><pub-id pub-id-type="pmid">20215135</pub-id><pub-id pub-id-type="pmcid">PMC2835511</pub-id></element-citation></ref><ref id="B102-vaccines-12-01220"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Merlin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Redd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uyeki</surname><given-names>T.M.</given-names></name></person-group><article-title>Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009&#8211;June 2010</article-title><source>Clin. Infect. Dis.</source><year>2012</year><volume>55</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/cid/cis352</pub-id><pub-id pub-id-type="pmid">22491506</pub-id></element-citation></ref><ref id="B103-vaccines-12-01220"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorbello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Struble</surname><given-names>K.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Truffa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Birnkrant</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Camilli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Emergency use authorization for intravenous peramivir: Evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus</article-title><source>Clin. Infect. Dis.</source><year>2012</year><volume>55</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/cid/cis351</pub-id><pub-id pub-id-type="pmid">22491501</pub-id></element-citation></ref><ref id="B104-vaccines-12-01220"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiraki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Daikoku</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</article-title><source>Pharmacol. Ther.</source><year>2020</year><volume>209</volume><fpage>107512</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107512</pub-id><pub-id pub-id-type="pmid">32097670</pub-id><pub-id pub-id-type="pmcid">PMC7102570</pub-id></element-citation></ref><ref id="B105-vaccines-12-01220"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colman</surname><given-names>P.M.</given-names></name></person-group><article-title>Zanamivir: An influenza virus neuraminidase inhibitor</article-title><source>Expert. Rev. Anti Infect. Ther.</source><year>2005</year><volume>3</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1586/14787210.3.2.191</pub-id><pub-id pub-id-type="pmid">15918777</pub-id></element-citation></ref><ref id="B106-vaccines-12-01220"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>L.J.</given-names></name></person-group><article-title>Peramivir: A Review in Uncomplicated Influenza</article-title><source>Drugs</source><year>2018</year><volume>78</volume><fpage>1363</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1007/s40265-018-0981-8</pub-id><pub-id pub-id-type="pmid">30196350</pub-id></element-citation></ref><ref id="B107-vaccines-12-01220"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.L.</given-names></name></person-group><article-title>Baloxavir marboxil: The new influenza drug on the market</article-title><source>Curr. Opin. Virol.</source><year>2019</year><volume>35</volume><fpage>14</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.01.006</pub-id><pub-id pub-id-type="pmid">30852344</pub-id></element-citation></ref><ref id="B108-vaccines-12-01220"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#246;lfel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Guggemos</surname><given-names>W.</given-names></name><name name-style="western"><surname>Seilmaier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zange</surname><given-names>S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Niemeyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Vollmar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rothe</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Virological assessment of hospitalized patients with COVID-2019</article-title><source>Nature</source><year>2020</year><volume>581</volume><fpage>465</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></element-citation></ref><ref id="B109-vaccines-12-01220"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vicenti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zazzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saladini</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19</article-title><source>Expert Opin. Ther. Pat.</source><year>2021</year><volume>31</volume><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1080/13543776.2021.1880568</pub-id><pub-id pub-id-type="pmid">33475441</pub-id><pub-id pub-id-type="pmcid">PMC7938656</pub-id></element-citation></ref><ref id="B110-vaccines-12-01220"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekheit</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>A.S.</given-names></name></person-group><article-title>Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>252</volume><fpage>115292</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115292</pub-id><pub-id pub-id-type="pmid">36965227</pub-id><pub-id pub-id-type="pmcid">PMC10023213</pub-id></element-citation></ref><ref id="B111-vaccines-12-01220"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabinger</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stiller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schmitzov&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dienemann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kokic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hillen</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>H&#246;bartner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>P.</given-names></name></person-group><article-title>Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis</article-title><source>Nat. Struct. Mol. Biol.</source><year>2021</year><volume>28</volume><fpage>740</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1038/s41594-021-00651-0</pub-id><pub-id pub-id-type="pmid">34381216</pub-id><pub-id pub-id-type="pmcid">PMC8437801</pub-id></element-citation></ref><ref id="B112-vaccines-12-01220"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials</article-title><source>Int. J. Antimicrob. Agents</source><year>2023</year><volume>62</volume><fpage>106870</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2023.106870</pub-id><pub-id pub-id-type="pmid">37245600</pub-id><pub-id pub-id-type="pmcid">PMC10214763</pub-id></element-citation></ref><ref id="B113-vaccines-12-01220"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourkarim</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pourtaghi-Anvarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>H.</given-names></name></person-group><article-title>Molnupiravir: A new candidate for COVID-19 treatment</article-title><source>Pharmacol. Res. Perspect.</source><year>2022</year><volume>10</volume><fpage>e00909</fpage><pub-id pub-id-type="doi">10.1002/prp2.909</pub-id><pub-id pub-id-type="pmid">34968008</pub-id><pub-id pub-id-type="pmcid">PMC8929331</pub-id></element-citation></ref><ref id="B114-vaccines-12-01220"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kovarova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K.H.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Madden</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Krzystek</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>De</surname><given-names>C.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801</article-title><source>Nature</source><year>2021</year><volume>591</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03312-w</pub-id><pub-id pub-id-type="pmid">33561864</pub-id><pub-id pub-id-type="pmcid">PMC7979515</pub-id></element-citation></ref><ref id="B115-vaccines-12-01220"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Painter</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bush</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Almazedi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eraut</surname><given-names>N.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Szewczyk</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Painter</surname><given-names>G.R.</given-names></name></person-group><article-title>Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2</article-title><source>Antimicrob. Agents Chemother.</source><year>2021</year><volume>65</volume><fpage>1110</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/AAC.02428-20</pub-id><pub-id pub-id-type="pmid">33649113</pub-id><pub-id pub-id-type="pmcid">PMC8092915</pub-id></element-citation></ref><ref id="B116-vaccines-12-01220"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name></person-group><article-title>Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?</article-title><source>Innovation</source><year>2021</year><volume>2</volume><fpage>100165</fpage><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100165</pub-id><pub-id pub-id-type="pmid">34518821</pub-id><pub-id pub-id-type="pmcid">PMC8425668</pub-id></element-citation></ref><ref id="B117-vaccines-12-01220"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furuta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Komeno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.</source><year>2017</year><volume>93</volume><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.2183/pjab.93.027</pub-id><pub-id pub-id-type="pmcid">PMC5713175</pub-id><pub-id pub-id-type="pmid">28769016</pub-id></element-citation></ref><ref id="B118-vaccines-12-01220"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sreekanth Reddy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>W.F.</given-names></name></person-group><article-title>Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options</article-title><source>Chembiochem</source><year>2021</year><volume>22</volume><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1002/cbic.202000595</pub-id><pub-id pub-id-type="pmid">33031623</pub-id><pub-id pub-id-type="pmcid">PMC7675336</pub-id></element-citation></ref><ref id="B119-vaccines-12-01220"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study</article-title><source>Infect. Drug Resist.</source><year>2021</year><volume>14</volume><fpage>5287</fpage><lpage>5291</lpage><pub-id pub-id-type="doi">10.2147/IDR.S330743</pub-id><pub-id pub-id-type="pmid">34916812</pub-id><pub-id pub-id-type="pmcid">PMC8672023</pub-id></element-citation></ref><ref id="B120-vaccines-12-01220"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Lung</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Tso</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1695</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id><pub-id pub-id-type="pmid">32401715</pub-id><pub-id pub-id-type="pmcid">PMC7211500</pub-id></element-citation></ref><ref id="B121-vaccines-12-01220"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tillekeratne</surname><given-names>L.M.V.</given-names></name></person-group><article-title>Potential SARS-CoV-2 main protease inhibitors</article-title><source>Drug Discov. Today</source><year>2021</year><volume>26</volume><fpage>804</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.12.005</pub-id><pub-id pub-id-type="pmid">33309533</pub-id><pub-id pub-id-type="pmcid">PMC7724992</pub-id></element-citation></ref><ref id="B122-vaccines-12-01220"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandwani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shuter</surname><given-names>J.</given-names></name></person-group><article-title>Lopinavir/ritonavir in the treatment of HIV-1 infection: A review</article-title><source>Ther. Clin. Risk Manag.</source><year>2008</year><volume>4</volume><fpage>1023</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.2147/tcrm.s3285</pub-id><pub-id pub-id-type="pmid">19209283</pub-id><pub-id pub-id-type="pmcid">PMC2621403</pub-id></element-citation></ref><ref id="B123-vaccines-12-01220"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loos</surname><given-names>N.H.C.</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name></person-group><article-title>The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>9866</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23179866</pub-id><pub-id pub-id-type="pmid">36077262</pub-id><pub-id pub-id-type="pmcid">PMC9456214</pub-id></element-citation></ref><ref id="B124-vaccines-12-01220"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>Y.N.</given-names></name></person-group><article-title>Nirmatrelvir Plus Ritonavir: First Approval</article-title><source>Drugs</source><year>2022</year><volume>82</volume><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01692-5</pub-id><pub-id pub-id-type="pmid">35305258</pub-id><pub-id pub-id-type="pmcid">PMC8933659</pub-id></element-citation></ref><ref id="B125-vaccines-12-01220"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feys</surname><given-names>J.R.</given-names></name></person-group><article-title>SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies</article-title><source>Future Pharmacol.</source><year>2023</year><volume>3</volume><fpage>80</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.3390/futurepharmacol3010006</pub-id></element-citation></ref><ref id="B126-vaccines-12-01220"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vries</surname><given-names>M.d.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Valero-Jimenez</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Desvignes</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Steppan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL&lt;sup&gt;pro&lt;/sup&gt; Inhibitor PF-00835231 as a Potential New Treatment for COVID-19</article-title><source>J. Virol.</source><year>2021</year><volume>95</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1128/jvi.01819-20</pub-id><pub-id pub-id-type="pmcid">PMC8139662</pub-id><pub-id pub-id-type="pmid">33622961</pub-id></element-citation></ref><ref id="B127-vaccines-12-01220"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ripoll</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>van Helmond</surname><given-names>N.</given-names></name><name name-style="western"><surname>Senefeld</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Wiggins</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Klassen</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Ford</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19</article-title><source>Clin. Microbiol. Newsl.</source><year>2021</year><volume>43</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.clinmicnews.2021.02.001</pub-id><pub-id pub-id-type="pmid">33564204</pub-id><pub-id pub-id-type="pmcid">PMC7862032</pub-id></element-citation></ref><ref id="B128-vaccines-12-01220"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id><pub-id pub-id-type="pmid">32219428</pub-id><pub-id pub-id-type="pmcid">PMC7101507</pub-id></element-citation></ref><ref id="B129-vaccines-12-01220"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pau</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Aberg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Belperio</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crew</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grund</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gulick</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel</article-title><source>Ann. Intern. Med.</source><year>2021</year><volume>174</volume><fpage>93</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.7326/M20-6448</pub-id><pub-id pub-id-type="pmid">32976026</pub-id><pub-id pub-id-type="pmcid">PMC7556653</pub-id></element-citation></ref><ref id="B130-vaccines-12-01220"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nomdedeu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sauleda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brillembourg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garc&#237;a-Vidal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Millan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Llonch</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19</article-title><source>Transfusion</source><year>2022</year><volume>62</volume><fpage>974</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1111/trf.16863</pub-id><pub-id pub-id-type="pmid">35338710</pub-id><pub-id pub-id-type="pmcid">PMC9115410</pub-id></element-citation></ref><ref id="B131-vaccines-12-01220"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Libster</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marc</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Wappner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braem</surname><given-names>V.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>I.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berrueta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2033700</pub-id><pub-id pub-id-type="pmid">33406353</pub-id><pub-id pub-id-type="pmcid">PMC7793608</pub-id></element-citation></ref><ref id="B132-vaccines-12-01220"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Focosi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Franchini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Burnouf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Paneth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Joyner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes</article-title><source>Clin. Microbiol. Rev.</source><year>2022</year><volume>35</volume><elocation-id>e0020021</elocation-id><pub-id pub-id-type="doi">10.1128/cmr.00200-21</pub-id><pub-id pub-id-type="pmid">35262370</pub-id><pub-id pub-id-type="pmcid">PMC9491201</pub-id></element-citation></ref><ref id="B133-vaccines-12-01220"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Z.</given-names></name></person-group><article-title>The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>964398</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.964398</pub-id><pub-id pub-id-type="pmid">35967398</pub-id><pub-id pub-id-type="pmcid">PMC9366612</pub-id></element-citation></ref><ref id="B134-vaccines-12-01220"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Focosi</surname><given-names>D.</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cappello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valdiserra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tuccori</surname><given-names>M.</given-names></name></person-group><article-title>Monoclonal antibody therapies against SARS-CoV-2</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>e311</fpage><lpage>e326</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00311-5</pub-id><pub-id pub-id-type="pmid">35803289</pub-id><pub-id pub-id-type="pmcid">PMC9255948</pub-id></element-citation></ref><ref id="B135-vaccines-12-01220"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wynia</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Beaty</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kwan</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients</article-title><source>Chest</source><year>2023</year><volume>163</volume><fpage>1061</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2022.10.020</pub-id><pub-id pub-id-type="pmid">36441040</pub-id><pub-id pub-id-type="pmcid">PMC9613796</pub-id></element-citation></ref><ref id="B136-vaccines-12-01220"><label>136.</label><element-citation publication-type="journal"><article-title>An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>880</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.24415</pub-id><pub-id pub-id-type="pmid">33306087</pub-id></element-citation></ref><ref id="B137-vaccines-12-01220"><label>137.</label><element-citation publication-type="journal"><article-title>An EUA for casirivimab and imdevimab for COVID-19</article-title><source>Med. Lett. Drugs Ther.</source><year>2020</year><volume>62</volume><fpage>201</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">33451174</pub-id></element-citation></ref><ref id="B138-vaccines-12-01220"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razonable</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Pawlowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Horo</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Arndt</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Arndt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bierle</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Borgen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Hedin</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lenehan</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19</article-title><source>EClinicalMedicine</source><year>2021</year><volume>40</volume><fpage>101102</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101102</pub-id><pub-id pub-id-type="pmid">34485873</pub-id><pub-id pub-id-type="pmcid">PMC8404031</pub-id></element-citation></ref><ref id="B139-vaccines-12-01220"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeks</surname><given-names>E.D.</given-names></name></person-group><article-title>Casirivimab/Imdevimab: First Approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>2047</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01620-z</pub-id><pub-id pub-id-type="pmid">34716907</pub-id><pub-id pub-id-type="pmcid">PMC8556815</pub-id></element-citation></ref><ref id="B140-vaccines-12-01220"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Nirula</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boscia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huhn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mocherla</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stosor</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.0202</pub-id><pub-id pub-id-type="pmid">33475701</pub-id><pub-id pub-id-type="pmcid">PMC7821080</pub-id></element-citation></ref><ref id="B141-vaccines-12-01220"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ben-Shlomo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Barda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kepten</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roitman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shapira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yaron</surname><given-names>S.</given-names></name><name name-style="western"><surname>Balicer</surname><given-names>R.D.</given-names></name><etal/></person-group><article-title>Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4480</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32253-9</pub-id><pub-id pub-id-type="pmid">35918340</pub-id><pub-id pub-id-type="pmcid">PMC9344792</pub-id></element-citation></ref><ref id="B142-vaccines-12-01220"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Kennerley</surname><given-names>V.</given-names></name><name name-style="western"><surname>Beaty</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Peers</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wynia</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>N.R.</given-names></name><etal/></person-group><article-title>Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5</article-title><source>Int. J. Infect. Dis.</source><year>2023</year><volume>132</volume><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2023.04.396</pub-id><pub-id pub-id-type="pmid">37072054</pub-id><pub-id pub-id-type="pmcid">PMC10106116</pub-id></element-citation></ref><ref id="B143-vaccines-12-01220"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>M.N.Y.</given-names></name><name name-style="western"><surname>Kua</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.W.H.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.K.</given-names></name></person-group><article-title>SARS-CoV-2 neutralizing antibody bebtelovimab&#8212;A systematic scoping review and meta-analysis</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1100263</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1100263</pub-id><pub-id pub-id-type="pmid">37701439</pub-id><pub-id pub-id-type="pmcid">PMC10494534</pub-id></element-citation></ref><ref id="B144-vaccines-12-01220"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hufford</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>de la Torre</surname><given-names>I.</given-names></name><name name-style="western"><surname>Winthrop</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>R.L.</given-names></name></person-group><article-title>Neutralizing monoclonal antibodies for treatment of COVID-19</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00542-x</pub-id><pub-id pub-id-type="pmid">33875867</pub-id><pub-id pub-id-type="pmcid">PMC8054133</pub-id></element-citation></ref><ref id="B145-vaccines-12-01220"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzaferri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mirandola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Savoldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Nardo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Morra</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tebon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armellini</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>G.</given-names></name><name name-style="western"><surname>Calandrino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sasset</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern</article-title><source>eLife</source><year>2022</year><volume>11</volume><fpage>e79639</fpage><pub-id pub-id-type="doi">10.7554/eLife.79639</pub-id><pub-id pub-id-type="pmid">36413383</pub-id><pub-id pub-id-type="pmcid">PMC9681201</pub-id></element-citation></ref><ref id="B146-vaccines-12-01220"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blair</surname><given-names>H.A.</given-names></name></person-group><article-title>Remdesivir: A Review in COVID-19</article-title><source>Drugs</source><year>2023</year><volume>83</volume><fpage>1215</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1007/s40265-023-01926-0</pub-id><pub-id pub-id-type="pmid">37589788</pub-id><pub-id pub-id-type="pmcid">PMC10474216</pub-id></element-citation></ref><ref id="B147-vaccines-12-01220"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syed</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Molnupiravir: First Approval</article-title><source>Drugs</source><year>2022</year><volume>82</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01684-5</pub-id><pub-id pub-id-type="pmid">35184266</pub-id><pub-id pub-id-type="pmcid">PMC8858220</pub-id></element-citation></ref><ref id="B148-vaccines-12-01220"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment</article-title><source>JAMA</source><year>2023</year><volume>329</volume><fpage>2118</fpage><pub-id pub-id-type="doi">10.1001/jama.2023.9925</pub-id><pub-id pub-id-type="pmid">37285173</pub-id></element-citation></ref><ref id="B149-vaccines-12-01220"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>Y.A.</given-names></name></person-group><article-title>Sotrovimab: First Approval</article-title><source>Drugs</source><year>2022</year><volume>82</volume><fpage>477</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01690-7</pub-id><pub-id pub-id-type="pmid">35286623</pub-id><pub-id pub-id-type="pmcid">PMC8919156</pub-id></element-citation></ref><ref id="B150-vaccines-12-01220"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Syed</surname><given-names>Y.Y.</given-names></name></person-group><article-title>Ensitrelvir Fumaric Acid: First Approval</article-title><source>Drugs</source><year>2024</year><volume>84</volume><fpage>721</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1007/s40265-024-02039-y</pub-id><pub-id pub-id-type="pmid">38795314</pub-id></element-citation></ref><ref id="B151-vaccines-12-01220"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>K.W.</given-names></name></person-group><article-title>Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19</article-title><source>ACS Pharmacol. Transl. Sci.</source><year>2023</year><volume>6</volume><fpage>1306</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.3c00134</pub-id><pub-id pub-id-type="pmid">37705591</pub-id><pub-id pub-id-type="pmcid">PMC10496140</pub-id></element-citation></ref><ref id="B152-vaccines-12-01220"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: A multicentre, double-blind, phase 3, randomised controlled study</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00577-7</pub-id><pub-id pub-id-type="pmid">38006892</pub-id></element-citation></ref><ref id="B153-vaccines-12-01220"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bijker</surname><given-names>E.M.</given-names></name></person-group><article-title>A guide to vaccinology: From basic principles to new developments</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>83</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id><pub-id pub-id-type="pmid">33353987</pub-id><pub-id pub-id-type="pmcid">PMC7754704</pub-id></element-citation></ref><ref id="B154-vaccines-12-01220"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson-Welder</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Kipper</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Mallapragada</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wannemuehler</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name></person-group><article-title>Vaccine adjuvants: Current challenges and future approaches</article-title><source>J. Pharm. Sci.</source><year>2009</year><volume>98</volume><fpage>1278</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1002/jps.21523</pub-id><pub-id pub-id-type="pmid">18704954</pub-id><pub-id pub-id-type="pmcid">PMC8092333</pub-id></element-citation></ref><ref id="B155-vaccines-12-01220"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Excler</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berkley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Vaccine development for emerging infectious diseases</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01301-0</pub-id><pub-id pub-id-type="pmid">33846611</pub-id></element-citation></ref><ref id="B156-vaccines-12-01220"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gillim-Ross</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Emerging respiratory viruses: Challenges and vaccine strategies</article-title><source>Clin. Microbiol. Rev.</source><year>2006</year><volume>19</volume><fpage>614</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1128/CMR.00005-06</pub-id><pub-id pub-id-type="pmid">17041137</pub-id><pub-id pub-id-type="pmcid">PMC1592697</pub-id></element-citation></ref><ref id="B157-vaccines-12-01220"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>D.</given-names></name><name name-style="western"><surname>King</surname><given-names>N.P.</given-names></name></person-group><article-title>New Vaccine Design and Delivery Technologies</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>219</volume><fpage>S88</fpage><lpage>S96</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy745</pub-id><pub-id pub-id-type="pmid">30715361</pub-id><pub-id pub-id-type="pmcid">PMC6452296</pub-id></element-citation></ref><ref id="B158-vaccines-12-01220"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vrba</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H.</given-names></name></person-group><article-title>Emerging Concepts and Technologies in Vaccine Development</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>583077</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.583077</pub-id><pub-id pub-id-type="pmid">33101309</pub-id><pub-id pub-id-type="pmcid">PMC7554600</pub-id></element-citation></ref><ref id="B159-vaccines-12-01220"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiMasi</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Florez</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Stergiopoulos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Getz</surname><given-names>K.A.</given-names></name></person-group><article-title>Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>107</volume><fpage>324</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1002/cpt.1627</pub-id><pub-id pub-id-type="pmid">31502248</pub-id></element-citation></ref><ref id="B160-vaccines-12-01220"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prompetchara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ketloy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palaga</surname><given-names>T.</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</article-title><source>Asian Pac. J. Allergy Immunol.</source><year>2020</year><volume>38</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.12932/ap-200220-0772</pub-id><pub-id pub-id-type="pmid">32105090</pub-id></element-citation></ref><ref id="B161-vaccines-12-01220"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.O.</given-names><suffix>3rd</suffix></name></person-group><article-title>The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation</article-title><source>AAPS PharmSciTech</source><year>2020</year><volume>21</volume><fpage>225</fpage><pub-id pub-id-type="doi">10.1208/s12249-020-01744-7</pub-id><pub-id pub-id-type="pmid">32761294</pub-id><pub-id pub-id-type="pmcid">PMC7405756</pub-id></element-citation></ref><ref id="B162-vaccines-12-01220"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Docea</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Petrakis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Egorov</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ishmukhametov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gabibov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Shtilman</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Kostoff</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vinceti</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review)</article-title><source>Int. J. Mol. Med.</source><year>2020</year><volume>46</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2020.4596</pub-id><pub-id pub-id-type="pmid">32377694</pub-id><pub-id pub-id-type="pmcid">PMC7255458</pub-id></element-citation></ref><ref id="B163-vaccines-12-01220"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minor</surname><given-names>P.D.</given-names></name></person-group><article-title>Live attenuated vaccines: Historical successes and current challenges</article-title><source>Virology</source><year>2015</year><volume>479&#8211;480</volume><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.03.032</pub-id><pub-id pub-id-type="pmid">25864107</pub-id></element-citation></ref><ref id="B164-vaccines-12-01220"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>A.S.</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title><source>J. Glob. Infect. Dis.</source><year>2011</year><volume>3</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmid">21572612</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id></element-citation></ref><ref id="B165-vaccines-12-01220"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghattas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lavertu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alameh</surname><given-names>M.G.</given-names></name></person-group><article-title>Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1490</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9121490</pub-id><pub-id pub-id-type="pmid">34960236</pub-id><pub-id pub-id-type="pmcid">PMC8708925</pub-id></element-citation></ref><ref id="B166-vaccines-12-01220"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elveborg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monteil</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Mirazimi</surname><given-names>A.</given-names></name></person-group><article-title>Methods of Inactivation of Highly Pathogenic Viruses for Molecular, Serology or Vaccine Development Purposes</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>271</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11020271</pub-id><pub-id pub-id-type="pmid">35215213</pub-id><pub-id pub-id-type="pmcid">PMC8879476</pub-id></element-citation></ref><ref id="B167-vaccines-12-01220"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Peptide-based synthetic vaccines</article-title><source>Chem. Sci.</source><year>2016</year><volume>7</volume><fpage>842</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1039/C5SC03892H</pub-id><pub-id pub-id-type="pmid">28791117</pub-id><pub-id pub-id-type="pmcid">PMC5529997</pub-id></element-citation></ref><ref id="B168-vaccines-12-01220"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vartak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sucheck</surname><given-names>S.J.</given-names></name></person-group><article-title>Recent Advances in Subunit Vaccine Carriers</article-title><source>Vaccines</source><year>2016</year><volume>4</volume><elocation-id>12</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines4020012</pub-id><pub-id pub-id-type="pmid">27104575</pub-id><pub-id pub-id-type="pmcid">PMC4931629</pub-id></element-citation></ref><ref id="B169-vaccines-12-01220"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foged</surname><given-names>C.</given-names></name></person-group><article-title>Subunit vaccines of the future: The need for safe, customized and optimized particulate delivery systems</article-title><source>Ther. Deliv.</source><year>2011</year><volume>2</volume><fpage>1057</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.4155/tde.11.68</pub-id><pub-id pub-id-type="pmid">22826868</pub-id></element-citation></ref><ref id="B170-vaccines-12-01220"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yazdi</surname><given-names>S.R.</given-names></name></person-group><article-title>DNA immunization as an efficient strategy for vaccination</article-title><source>Avicenna J. Med. Biotechnol.</source><year>2009</year><volume>1</volume><fpage>71</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23407787</pub-id><pub-id pub-id-type="pmcid">PMC3558129</pub-id></element-citation></ref><ref id="B171-vaccines-12-01220"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neeli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sobhani</surname><given-names>N.</given-names></name><name name-style="western"><surname>K</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kurapati</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1332939</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1332939</pub-id><pub-id pub-id-type="pmid">38361919</pub-id><pub-id pub-id-type="pmcid">PMC10867258</pub-id></element-citation></ref><ref id="B172-vaccines-12-01220"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name></person-group><article-title>DNA Vaccines: Their Formulations, Engineering and Delivery</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12010071</pub-id><pub-id pub-id-type="pmid">38250884</pub-id><pub-id pub-id-type="pmcid">PMC10820593</pub-id></element-citation></ref><ref id="B173-vaccines-12-01220"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Wahren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>Gene-based vaccines: Recent technical and clinical advances</article-title><source>Trends Mol. Med.</source><year>2006</year><volume>12</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2006.03.007</pub-id><pub-id pub-id-type="pmid">16621717</pub-id></element-citation></ref><ref id="B174-vaccines-12-01220"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T.</given-names></name></person-group><article-title>mRNA vaccines in disease prevention and treatment</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01579-1</pub-id><pub-id pub-id-type="pmid">37726283</pub-id><pub-id pub-id-type="pmcid">PMC10509165</pub-id></element-citation></ref><ref id="B175-vaccines-12-01220"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name></person-group><article-title>mRNA vaccine: A potential therapeutic strategy</article-title><source>Mol. Cancer</source><year>2021</year><volume>20</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01311-z</pub-id><pub-id pub-id-type="pmid">33593376</pub-id><pub-id pub-id-type="pmcid">PMC7884263</pub-id></element-citation></ref><ref id="B176-vaccines-12-01220"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kutikuppala</surname><given-names>L.V.S.</given-names></name><name name-style="western"><surname>Kourampi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kanagala</surname><given-names>R.S.D.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boppana</surname><given-names>S.H.</given-names></name></person-group><article-title>Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses</article-title><source>Med. Sci.</source><year>2024</year><volume>12</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3390/medsci12020028</pub-id><pub-id pub-id-type="pmcid">PMC11130901</pub-id><pub-id pub-id-type="pmid">38804384</pub-id></element-citation></ref><ref id="B177-vaccines-12-01220"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deering</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Kommareddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Geall</surname><given-names>A.J.</given-names></name></person-group><article-title>Nucleic acid vaccines: Prospects for non-viral delivery of mRNA vaccines</article-title><source>Expert Opin. Drug Deliv.</source><year>2014</year><volume>11</volume><fpage>885</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1517/17425247.2014.901308</pub-id><pub-id pub-id-type="pmid">24665982</pub-id></element-citation></ref><ref id="B178-vaccines-12-01220"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>K.A.</given-names></name></person-group><article-title>mRNA vaccines for infectious diseases: Principles, delivery and clinical translation</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>817</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00283-5</pub-id><pub-id pub-id-type="pmid">34433919</pub-id><pub-id pub-id-type="pmcid">PMC8386155</pub-id></element-citation></ref><ref id="B179-vaccines-12-01220"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>C.W.</given-names></name></person-group><article-title>A history of influenza</article-title><source>J. Appl. Microbiol.</source><year>2001</year><volume>91</volume><fpage>572</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2672.2001.01492.x</pub-id><pub-id pub-id-type="pmid">11576290</pub-id></element-citation></ref><ref id="B180-vaccines-12-01220"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smyk</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Szyd&#322;owska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Szulc</surname><given-names>W.</given-names></name><name name-style="western"><surname>Majewska</surname><given-names>A.</given-names></name></person-group><article-title>Evolution of influenza viruses&#8212;Drug resistance, treatment options, and prospects</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>12244</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232012244</pub-id><pub-id pub-id-type="pmid">36293099</pub-id><pub-id pub-id-type="pmcid">PMC9602850</pub-id></element-citation></ref><ref id="B181-vaccines-12-01220"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iuliano</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Roguski</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Muscatello</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Palekar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tempia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gran</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schanzer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Estimates of global seasonal influenza-associated respiratory mortality: A modelling study</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1285</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id><pub-id pub-id-type="pmid">29248255</pub-id><pub-id pub-id-type="pmcid">PMC5935243</pub-id></element-citation></ref><ref id="B182-vaccines-12-01220"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saunders-Hastings</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Krewski</surname><given-names>D.</given-names></name></person-group><article-title>Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and Transmission</article-title><source>Pathogens</source><year>2016</year><volume>5</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens5040066</pub-id><pub-id pub-id-type="pmid">27929449</pub-id><pub-id pub-id-type="pmcid">PMC5198166</pub-id></element-citation></ref><ref id="B183-vaccines-12-01220"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coletti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poletto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Turbelin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blanchon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Colizza</surname><given-names>V.</given-names></name></person-group><article-title>Shifting patterns of seasonal influenza epidemics</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>12786</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-30949-x</pub-id><pub-id pub-id-type="pmid">30143689</pub-id><pub-id pub-id-type="pmcid">PMC6109160</pub-id></element-citation></ref><ref id="B184-vaccines-12-01220"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Cowling</surname><given-names>B.J.</given-names></name></person-group><article-title>Influenza Virus: Tracking, Predicting, and Forecasting</article-title><source>Annu. Rev. Public Health</source><year>2021</year><volume>42</volume><fpage>43</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1146/annurev-publhealth-010720-021049</pub-id><pub-id pub-id-type="pmid">33348997</pub-id></element-citation></ref><ref id="B185-vaccines-12-01220"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zambon</surname><given-names>M.C.</given-names></name></person-group><article-title>The pathogenesis of influenza in humans</article-title><source>Rev. Med. Virol.</source><year>2001</year><volume>11</volume><fpage>227</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1002/rmv.319</pub-id><pub-id pub-id-type="pmid">11479929</pub-id></element-citation></ref><ref id="B186-vaccines-12-01220"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasten-Jolly</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>D.A.</given-names></name></person-group><article-title>Cellular and Molecular Immunity to Influenza Viruses and Vaccines</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>389</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12040389</pub-id><pub-id pub-id-type="pmid">38675771</pub-id><pub-id pub-id-type="pmcid">PMC11154265</pub-id></element-citation></ref><ref id="B187-vaccines-12-01220"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nuwarda</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>V.</given-names></name></person-group><article-title>An Overview of Influenza Viruses and Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1032</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9091032</pub-id><pub-id pub-id-type="pmid">34579269</pub-id><pub-id pub-id-type="pmcid">PMC8473132</pub-id></element-citation></ref><ref id="B188-vaccines-12-01220"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Advances in the development of influenza virus vaccines</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>167</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nrd4529</pub-id><pub-id pub-id-type="pmid">25722244</pub-id></element-citation></ref><ref id="B189-vaccines-12-01220"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabbaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Miri</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Keshavarz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zargar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghaemi</surname><given-names>A.</given-names></name></person-group><article-title>Inactivation methods for whole influenza vaccine production</article-title><source>Rev. Med. Virol.</source><year>2019</year><volume>29</volume><fpage>e2074</fpage><pub-id pub-id-type="doi">10.1002/rmv.2074</pub-id><pub-id pub-id-type="pmid">31334909</pub-id></element-citation></ref><ref id="B190-vaccines-12-01220"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>T.J.S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Presler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Development of an Enhanced High-Yield Influenza Vaccine Backbone in Embryonated Chicken Eggs</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1364</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11081364</pub-id><pub-id pub-id-type="pmid">37631932</pub-id><pub-id pub-id-type="pmcid">PMC10459923</pub-id></element-citation></ref><ref id="B191-vaccines-12-01220"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>C.B.</given-names></name></person-group><article-title>Propagation and Characterization of Influenza Virus Stocks That Lack High Levels of Defective Viral Genomes and Hemagglutinin Mutations</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>326</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.00326</pub-id><pub-id pub-id-type="pmid">27047455</pub-id><pub-id pub-id-type="pmcid">PMC4803753</pub-id></element-citation></ref><ref id="B192-vaccines-12-01220"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddback</surname><given-names>I.E.M.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>L.M.I.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Steffensen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Holst</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>J.P.</given-names></name></person-group><article-title>Combined local and systemic immunization is essential for durable T-cell mediated heterosubtypic immunity against influenza A virus</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>20137</elocation-id><pub-id pub-id-type="doi">10.1038/srep20137</pub-id><pub-id pub-id-type="pmid">26831578</pub-id><pub-id pub-id-type="pmcid">PMC4735591</pub-id></element-citation></ref><ref id="B193-vaccines-12-01220"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Traditional and new influenza vaccines</article-title><source>Clin. Microbiol. Rev.</source><year>2013</year><volume>26</volume><fpage>476</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1128/CMR.00097-12</pub-id><pub-id pub-id-type="pmid">23824369</pub-id><pub-id pub-id-type="pmcid">PMC3719499</pub-id></element-citation></ref><ref id="B194-vaccines-12-01220"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>D.W.</given-names></name></person-group><article-title>Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections</article-title><source>J. Immunol.</source><year>2011</year><volume>186</volume><fpage>987</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002664</pub-id><pub-id pub-id-type="pmid">21160043</pub-id></element-citation></ref><ref id="B195-vaccines-12-01220"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohn</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Brokstad</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oftung</surname><given-names>F.</given-names></name><name name-style="western"><surname>T&#248;ndel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aarstad</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Early induction of cross-reactive CD8+ T-cell responses in tonsils after live-attenuated influenza vaccination in children</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>1528</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz583</pub-id><pub-id pub-id-type="pmid">32255493</pub-id><pub-id pub-id-type="pmcid">PMC7137893</pub-id></element-citation></ref><ref id="B196-vaccines-12-01220"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Coelingh</surname><given-names>K.</given-names></name></person-group><article-title>Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines</article-title><source>Viral Immunol.</source><year>2002</year><volume>15</volume><fpage>295</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1089/08828240260066242</pub-id><pub-id pub-id-type="pmid">12081014</pub-id></element-citation></ref><ref id="B197-vaccines-12-01220"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maassab</surname><given-names>H.</given-names></name></person-group><article-title>Biologic and immunologic characteristics of cold-adapted influenza virus</article-title><source>J. Immunol.</source><year>1969</year><volume>102</volume><fpage>728</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.102.3.728</pub-id><pub-id pub-id-type="pmid">5773321</pub-id></element-citation></ref><ref id="B198-vaccines-12-01220"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Hollister</surname><given-names>J.R.</given-names></name></person-group><article-title>FluBlok, a next generation influenza vaccine manufactured in insect cells</article-title><source>Biologicals</source><year>2009</year><volume>37</volume><fpage>182</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2009.02.014</pub-id><pub-id pub-id-type="pmid">19297194</pub-id></element-citation></ref><ref id="B199-vaccines-12-01220"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geisler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>D.L.</given-names></name></person-group><article-title>Adventitious viruses in insect cell lines used for recombinant protein expression</article-title><source>Protein Expr. Purif.</source><year>2018</year><volume>144</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.pep.2017.11.002</pub-id><pub-id pub-id-type="pmid">29133148</pub-id><pub-id pub-id-type="pmcid">PMC5826799</pub-id></element-citation></ref><ref id="B200-vaccines-12-01220"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grohskopf</surname><given-names>L.A.</given-names></name></person-group><article-title>Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices&#8212;United States, 2019&#8211;2020 influenza season</article-title><source>MMWR Recomm. Rep.</source><year>2019</year><volume>68</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.15585/mmwr.rr6803a1</pub-id><pub-id pub-id-type="pmcid">PMC6713402</pub-id><pub-id pub-id-type="pmid">31441906</pub-id></element-citation></ref><ref id="B201-vaccines-12-01220"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moritzky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Branche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Topham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Treanor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sant</surname><given-names>A.J.</given-names></name></person-group><article-title>Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans</article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>77</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-00227-x</pub-id><pub-id pub-id-type="pmid">32884842</pub-id><pub-id pub-id-type="pmcid">PMC7450042</pub-id></element-citation></ref><ref id="B202-vaccines-12-01220"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutierrez</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Sahly</surname><given-names>H.E.</given-names></name></person-group><article-title>Recombinant hemagglutinin protein vaccine: A new option in immunization against influenza</article-title><source>Future Virol.</source><year>2015</year><volume>10</volume><fpage>1057</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.2217/fvl.15.75</pub-id></element-citation></ref><ref id="B203-vaccines-12-01220"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>B.</given-names></name></person-group><article-title>Understanding of COVID-19 based on current evidence</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1002/jmv.25722</pub-id><pub-id pub-id-type="pmid">32096567</pub-id><pub-id pub-id-type="pmcid">PMC7228250</pub-id></element-citation></ref><ref id="B204-vaccines-12-01220"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agor</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>&#214;zalt&#305;n</surname><given-names>O.Y.</given-names></name></person-group><article-title>Models for predicting the evolution of influenza to inform vaccine strain selection</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>678</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1423152</pub-id><pub-id pub-id-type="pmid">29337643</pub-id><pub-id pub-id-type="pmcid">PMC5861780</pub-id></element-citation></ref><ref id="B205-vaccines-12-01220"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanney</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Wooding</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sussex</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>J.</given-names></name></person-group><article-title>From COVID-19 research to vaccine application: Why might it take 17&#8201;months not 17&#8201;years and what are the wider lessons?</article-title><source>Health Res. Policy Syst.</source><year>2020</year><volume>18</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s12961-020-00571-3</pub-id><pub-id pub-id-type="pmid">32513202</pub-id><pub-id pub-id-type="pmcid">PMC7276964</pub-id></element-citation></ref><ref id="B206-vaccines-12-01220"><label>206.</label><element-citation publication-type="webpage"><article-title>Approved Vaccines</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list" ext-link-type="uri">https://covid19.trackvaccines.org/vaccines/approved/#vaccine-list</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-02">(accessed on 2 December 2022)</date-in-citation></element-citation></ref><ref id="B207-vaccines-12-01220"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoshnood</surname><given-names>S.</given-names></name><name name-style="western"><surname>Arshadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akrami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koupaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghahramanpour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shariati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sadeghifard</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heidary</surname><given-names>M.</given-names></name></person-group><article-title>An overview on inactivated and live-attenuated SARS-CoV-2 vaccines</article-title><source>J. Clin. Lab. Anal.</source><year>2022</year><volume>36</volume><fpage>e24418</fpage><pub-id pub-id-type="doi">10.1002/jcla.24418</pub-id><pub-id pub-id-type="pmid">35421266</pub-id><pub-id pub-id-type="pmcid">PMC9102488</pub-id></element-citation></ref><ref id="B208-vaccines-12-01220"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delrue</surname><given-names>I.</given-names></name><name name-style="western"><surname>Verzele</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges</article-title><source>Expert Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>695</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1586/erv.12.38</pub-id><pub-id pub-id-type="pmid">22873127</pub-id></element-citation></ref><ref id="B209-vaccines-12-01220"><label>209.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>WHO COVID-19 Dashboard</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" ext-link-type="uri">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-28">(accessed on 28 March 2024)</date-in-citation></element-citation></ref><ref id="B210-vaccines-12-01220"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="B211-vaccines-12-01220"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Kaabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Al Qahtani</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Abdulrazzaq</surname><given-names>N.</given-names></name><name name-style="western"><surname>Al Nusair</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassany</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jawad</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Abdalla</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.8565</pub-id><pub-id pub-id-type="pmid">34037666</pub-id><pub-id pub-id-type="pmcid">PMC8156175</pub-id></element-citation></ref><ref id="B212-vaccines-12-01220"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Duong</surname><given-names>H.N.V.</given-names></name><name name-style="western"><surname>Lenh</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Ta</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Trieu</surname><given-names>N.N.M.</given-names></name><etal/></person-group><article-title>Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam</article-title><source>Hum. Vaccin. Immunother.</source><year>2023</year><volume>19</volume><fpage>2176066</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2176066</pub-id><pub-id pub-id-type="pmid">36856074</pub-id><pub-id pub-id-type="pmcid">PMC10026889</pub-id></element-citation></ref><ref id="B213-vaccines-12-01220"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><volume>21</volume><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="B214-vaccines-12-01220"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asokan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Joan</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Babji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dayma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nadukkandy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Subrahmanyam</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malagi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mahajan</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN&#174;) and ChAdOx1 nCoV-19 (COVISHIELD&#8482;) in seronegative and seropositive individuals in India: A multicentre, nonrandomised observational study</article-title><source>Lancet Reg. Health-Southeast Asia</source><year>2024</year><volume>22</volume><fpage>100361</fpage><pub-id pub-id-type="doi">10.1016/j.lansea.2024.100361</pub-id><pub-id pub-id-type="pmid">38482152</pub-id><pub-id pub-id-type="pmcid">PMC10934322</pub-id></element-citation></ref><ref id="B215-vaccines-12-01220"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vikkurthi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pai</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Jha</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sachan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nikam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kalia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jit</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Parray</surname><given-names>H.A.</given-names></name><etal/></person-group><article-title>Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern</article-title><source>Nat. Microbiol.</source><year>2022</year><volume>7</volume><fpage>974</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01161-5</pub-id><pub-id pub-id-type="pmid">35681012</pub-id></element-citation></ref><ref id="B216-vaccines-12-01220"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zasada</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Darli&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiatrzyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wo&#378;nica</surname><given-names>K.</given-names></name><name name-style="western"><surname>Formi&#324;ska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Czajka</surname><given-names>U.</given-names></name><name name-style="western"><surname>G&#322;&#243;wka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lis</surname><given-names>K.</given-names></name><name name-style="western"><surname>G&#243;rska</surname><given-names>P.</given-names></name></person-group><article-title>COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1786</elocation-id><pub-id pub-id-type="doi">10.3390/v15091786</pub-id><pub-id pub-id-type="pmid">37766194</pub-id><pub-id pub-id-type="pmcid">PMC10536649</pub-id></element-citation></ref><ref id="B217-vaccines-12-01220"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordeychuk</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Kozlovskaya</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Siniugina</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Yagovkina</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Kuzubov</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Zakharov</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Volok</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Dodina</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Gmyl</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Korotina</surname><given-names>N.A.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18&#8211;60 and 60+ Age Cohorts</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1828</elocation-id><pub-id pub-id-type="doi">10.3390/v15091828</pub-id><pub-id pub-id-type="pmid">37766235</pub-id><pub-id pub-id-type="pmcid">PMC10537914</pub-id></element-citation></ref><ref id="B218-vaccines-12-01220"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulitzky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title><source>Viral Immunol.</source><year>2013</year><volume>26</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1089/vim.2012.0076</pub-id><pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></element-citation></ref><ref id="B219-vaccines-12-01220"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Adjuvants for Coronavirus Vaccines</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>589833</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.589833</pub-id><pub-id pub-id-type="pmid">33240278</pub-id><pub-id pub-id-type="pmcid">PMC7677582</pub-id></element-citation></ref><ref id="B220-vaccines-12-01220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bhikha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoosain</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Archary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>U.</given-names></name><name name-style="western"><surname>Masilela</surname><given-names>M.S.L.</given-names></name><name name-style="western"><surname>Moodley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>1899</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2103055</pub-id><pub-id pub-id-type="pmid">33951374</pub-id><pub-id pub-id-type="pmcid">PMC8091623</pub-id></element-citation></ref><ref id="B221-vaccines-12-01220"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Haupt</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weston</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>H.</given-names></name><name name-style="western"><surname>Logue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Portnoff</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guebre-Xabier</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20653-8</pub-id><pub-id pub-id-type="pmid">33446655</pub-id><pub-id pub-id-type="pmcid">PMC7809486</pub-id></element-citation></ref><ref id="B222-vaccines-12-01220"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirsebom</surname><given-names>F.C.M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dabrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lopez Bernal</surname><given-names>J.</given-names></name></person-group><article-title>Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England</article-title><source>eClinicalMedicine</source><year>2024</year><volume>71</volume><fpage>102587</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102587</pub-id><pub-id pub-id-type="pmid">38618208</pub-id><pub-id pub-id-type="pmcid">PMC11015482</pub-id></element-citation></ref><ref id="B223-vaccines-12-01220"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayan</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grunenberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Antony</surname><given-names>J.</given-names></name><name name-style="western"><surname>Asante</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Bhate</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Beresnev</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: A phase 3, parallel, randomised, modified double-blind, placebo-controlled trial</article-title><source>Lancet Respir. Med.</source><year>2023</year><volume>11</volume><fpage>975</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(23)00263-1</pub-id><pub-id pub-id-type="pmid">37716365</pub-id><pub-id pub-id-type="pmcid">PMC10872639</pub-id></element-citation></ref><ref id="B224-vaccines-12-01220"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Advances in mRNA vaccines for infectious diseases</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>594</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></element-citation></ref><ref id="B225-vaccines-12-01220"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Echaide</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chocarro de Erauso</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bocanegra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kochan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Escors</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines against SARS-CoV-2: Advantages and caveats</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>5944</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24065944</pub-id><pub-id pub-id-type="pmid">36983017</pub-id><pub-id pub-id-type="pmcid">PMC10051235</pub-id></element-citation></ref><ref id="B226-vaccines-12-01220"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamb</surname><given-names>Y.N.</given-names></name></person-group><article-title>BNT162b2 mRNA COVID-19 Vaccine: First Approval</article-title><source>Drugs</source><year>2021</year><volume>81</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1007/s40265-021-01480-7</pub-id><pub-id pub-id-type="pmid">33683637</pub-id><pub-id pub-id-type="pmcid">PMC7938284</pub-id></element-citation></ref><ref id="B227-vaccines-12-01220"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Frenck Jr</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name></person-group><article-title>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></element-citation></ref><ref id="B228-vaccines-12-01220"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="B229-vaccines-12-01220"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tartof</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Slezak</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Ranasinghe</surname><given-names>O.N.</given-names></name><name name-style="western"><surname>Frankland</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Ogun</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Zamparo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1407</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02183-8</pub-id><pub-id pub-id-type="pmid">34619098</pub-id><pub-id pub-id-type="pmcid">PMC8489881</pub-id></element-citation></ref><ref id="B230-vaccines-12-01220"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="B231-vaccines-12-01220"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shabu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nishtala</surname><given-names>P.S.</given-names></name></person-group><article-title>Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): A literature review</article-title><source>Expert Rev. Vaccines</source><year>2023</year><volume>22</volume><fpage>393</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1080/14760584.2023.2209177</pub-id><pub-id pub-id-type="pmid">37133747</pub-id></element-citation></ref><ref id="B232-vaccines-12-01220"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Nuismer</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Antia</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant vector vaccine evolution</article-title><source>PLoS Comput. Biol.</source><year>2019</year><volume>15</volume><elocation-id>e1006857</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006857</pub-id><pub-id pub-id-type="pmid">31323032</pub-id><pub-id pub-id-type="pmcid">PMC6668849</pub-id></element-citation></ref><ref id="B233-vaccines-12-01220"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>P.C.H.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>King</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name></person-group><article-title>Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1010821</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010821</pub-id><pub-id pub-id-type="pmid">36129963</pub-id><pub-id pub-id-type="pmcid">PMC9491521</pub-id></element-citation></ref><ref id="B234-vaccines-12-01220"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Crielesi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fabiani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salvatore Miglietta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colaiocco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pasqua</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vivaldi</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy)</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>2540</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.02.063</pub-id><pub-id pub-id-type="pmid">35341646</pub-id><pub-id pub-id-type="pmcid">PMC8938180</pub-id></element-citation></ref><ref id="B235-vaccines-12-01220"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>S.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>2348</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2105290</pub-id><pub-id pub-id-type="pmid">34587382</pub-id><pub-id pub-id-type="pmcid">PMC8522798</pub-id></element-citation></ref><ref id="B236-vaccines-12-01220"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huiberts</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>de Gier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoeve</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>de Melker</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Hahn&#233;</surname><given-names>S.J.M.</given-names></name><name name-style="western"><surname>den Hartog</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grobbee</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>van de Wijgert</surname><given-names>J.H.H.M.</given-names></name><name name-style="western"><surname>van den Hof</surname><given-names>S.</given-names></name><name name-style="western"><surname>Knol</surname><given-names>M.J.</given-names></name></person-group><article-title>Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study</article-title><source>Int. J. Infect. Dis.</source><year>2023</year><volume>133</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2023.04.401</pub-id><pub-id pub-id-type="pmid">37086863</pub-id><pub-id pub-id-type="pmcid">PMC10118053</pub-id></element-citation></ref><ref id="B237-vaccines-12-01220"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Potluri</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Kahar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>D.</given-names></name></person-group><article-title>A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna &amp; Johnson &amp; Johnson</article-title><source>Hum. Vaccin. Immunother.</source><year>2022</year><volume>18</volume><fpage>2002083</fpage><pub-id pub-id-type="doi">10.1080/21645515.2021.2002083</pub-id><pub-id pub-id-type="pmid">35130825</pub-id><pub-id pub-id-type="pmcid">PMC8862159</pub-id></element-citation></ref><ref id="B238-vaccines-12-01220"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lubenets</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="B239-vaccines-12-01220"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>I.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>P.</given-names></name></person-group><article-title>Sputnik V COVID-19 vaccine candidate appears safe and effective</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>642</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00191-4</pub-id><pub-id pub-id-type="pmid">33545098</pub-id><pub-id pub-id-type="pmcid">PMC7906719</pub-id></element-citation></ref><ref id="B240-vaccines-12-01220"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>COVID-19 Vaccines: Where Did We Stand at the End of 2023?</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>203</elocation-id><pub-id pub-id-type="doi">10.3390/v16020203</pub-id><pub-id pub-id-type="pmid">38399979</pub-id><pub-id pub-id-type="pmcid">PMC10893040</pub-id></element-citation></ref><ref id="B241-vaccines-12-01220"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elrashdy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Redwan</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Uversky</surname><given-names>V.N.</given-names></name></person-group><article-title>Why COVID-19 Transmission Is More Efficient and Aggressive Than Viral Transmission in Previous Coronavirus Epidemics?</article-title><source>Biomolecules</source><year>2020</year><volume>10</volume><elocation-id>1312</elocation-id><pub-id pub-id-type="doi">10.3390/biom10091312</pub-id><pub-id pub-id-type="pmid">32933047</pub-id><pub-id pub-id-type="pmcid">PMC7565143</pub-id></element-citation></ref><ref id="B242-vaccines-12-01220"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carabelli</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Thorne</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Towers</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 variant biology: Immune escape, transmission and fitness</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>162</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00841-7</pub-id><pub-id pub-id-type="pmid">36653446</pub-id><pub-id pub-id-type="pmcid">PMC9847462</pub-id></element-citation></ref><ref id="B243-vaccines-12-01220"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Einav</surname><given-names>S.</given-names></name></person-group><article-title>Preparing for the next viral threat with broad-spectrum antivirals</article-title><source>J. Clin. Investig.</source><year>2023</year><volume>133</volume><fpage>e170236</fpage><pub-id pub-id-type="doi">10.1172/JCI170236</pub-id><pub-id pub-id-type="pmid">37259914</pub-id><pub-id pub-id-type="pmcid">PMC10232003</pub-id></element-citation></ref><ref id="B244-vaccines-12-01220"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hagey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Elazar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ben-Avi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bernardin-Souibgui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Rabinovitch</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Meganck</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1944</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01908-x</pub-id><pub-id pub-id-type="pmid">35982307</pub-id><pub-id pub-id-type="pmcid">PMC10132811</pub-id></element-citation></ref><ref id="B245-vaccines-12-01220"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sodani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S.</given-names></name></person-group><article-title>Host directed therapies: COVID-19 and beyond</article-title><source>Curr. Res. Pharmacol. Drug Discov.</source><year>2021</year><volume>2</volume><fpage>100058</fpage><pub-id pub-id-type="doi">10.1016/j.crphar.2021.100058</pub-id><pub-id pub-id-type="pmid">34870156</pub-id><pub-id pub-id-type="pmcid">PMC8464038</pub-id></element-citation></ref><ref id="B246-vaccines-12-01220"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name></person-group><article-title>Status and Developing Strategies for Neutralizing Monoclonal Antibody Therapy in the Omicron Era of COVID-19</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1297</elocation-id><pub-id pub-id-type="doi">10.3390/v15061297</pub-id><pub-id pub-id-type="pmid">37376597</pub-id><pub-id pub-id-type="pmcid">PMC10302031</pub-id></element-citation></ref><ref id="B247-vaccines-12-01220"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mengist</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kombe Kombe</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Mekonnen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abebaw</surname><given-names>A.</given-names></name><name name-style="western"><surname>Getachew</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>T.</given-names></name></person-group><article-title>Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity</article-title><source>Semin. Immunol.</source><year>2021</year><volume>55</volume><fpage>101533</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2021.101533</pub-id><pub-id pub-id-type="pmid">34836774</pub-id><pub-id pub-id-type="pmcid">PMC8604694</pub-id></element-citation></ref><ref id="B248-vaccines-12-01220"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Low</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Farouk</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S.K.</given-names></name></person-group><article-title>Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>1058</elocation-id><pub-id pub-id-type="doi">10.3390/v12091058</pub-id><pub-id pub-id-type="pmid">32972027</pub-id><pub-id pub-id-type="pmcid">PMC7551028</pub-id></element-citation></ref><ref id="B249-vaccines-12-01220"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zabidi</surname><given-names>N.Z.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Farouk</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Puniyamurti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>Wijesinghe</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Low</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>V.T.K.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S.K.</given-names></name></person-group><article-title>Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>944</elocation-id><pub-id pub-id-type="doi">10.3390/v15040944</pub-id><pub-id pub-id-type="pmid">37112923</pub-id><pub-id pub-id-type="pmcid">PMC10145020</pub-id></element-citation></ref><ref id="B250-vaccines-12-01220"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Albery</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Merow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trisos</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Zipfel</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Eskew</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Olival</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bansal</surname><given-names>S.</given-names></name></person-group><article-title>Climate change increases cross-species viral transmission risk</article-title><source>Nature</source><year>2022</year><volume>607</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04788-w</pub-id><pub-id pub-id-type="pmid">35483403</pub-id></element-citation></ref><ref id="B251-vaccines-12-01220"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Redondo</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Sant&#8217;Anna Carvalho</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Hultquist</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Ozer</surname><given-names>E.A.</given-names></name></person-group><article-title>SARS-CoV-2 genomics and impact on clinical care for COVID-19</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>ii25</fpage><lpage>ii36</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad309</pub-id><pub-id pub-id-type="pmid">37995357</pub-id><pub-id pub-id-type="pmcid">PMC10667012</pub-id></element-citation></ref><ref id="B252-vaccines-12-01220"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Telenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arvin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Virgin</surname><given-names>H.W.</given-names></name></person-group><article-title>After the pandemic: Perspectives on the future trajectory of COVID-19</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03792-w</pub-id><pub-id pub-id-type="pmid">34237771</pub-id></element-citation></ref><ref id="B253-vaccines-12-01220"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>N.T.P.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alarifi</surname><given-names>A.</given-names></name><name name-style="western"><surname>kenawy</surname><given-names>E.-R.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Hasnain</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Nayak</surname><given-names>A.K.</given-names></name></person-group><article-title>Global impacts of pre- and post-COVID-19 pandemic: Focus on socio-economic consequences</article-title><source>Sens. Int.</source><year>2020</year><volume>1</volume><fpage>100042</fpage><pub-id pub-id-type="doi">10.1016/j.sintl.2020.100042</pub-id><pub-id pub-id-type="pmid">34766044</pub-id><pub-id pub-id-type="pmcid">PMC7510561</pub-id></element-citation></ref><ref id="B254-vaccines-12-01220"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>dos Santos</surname><given-names>W.G.</given-names></name></person-group><article-title>Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>136</volume><elocation-id>111272</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111272</pub-id><pub-id pub-id-type="pmid">33486212</pub-id><pub-id pub-id-type="pmcid">PMC7802525</pub-id></element-citation></ref><ref id="B255-vaccines-12-01220"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>V.</given-names></name><name name-style="western"><surname>True</surname><given-names>J.M.</given-names></name></person-group><article-title>Outlook of pandemic preparedness in a post-COVID-19 world</article-title><source>npj Vaccines</source><year>2023</year><volume>8</volume><fpage>178</fpage><pub-id pub-id-type="doi">10.1038/s41541-023-00773-0</pub-id><pub-id pub-id-type="pmid">37985781</pub-id><pub-id pub-id-type="pmcid">PMC10662147</pub-id></element-citation></ref><ref id="B256-vaccines-12-01220"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vijay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bedi</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Dhaka</surname><given-names>P.</given-names></name></person-group><article-title>Surveillance and response strategies for zoonotic diseases: A comprehensive review</article-title><source>Sci. One Health</source><year>2023</year><volume>2</volume><fpage>100050</fpage><pub-id pub-id-type="doi">10.1016/j.soh.2023.100050</pub-id><pub-id pub-id-type="pmid">39077041</pub-id><pub-id pub-id-type="pmcid">PMC11262259</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01220-f001" orientation="portrait"><label>Figure 1</label><caption><p>Respiratory virus infection, pathophysiology, and immune system activation. Once a respiratory virus enters the body via the nasopharyngeal route, viral particles penetrate the mucus and bronchial epithelial layer, damaging these cells and reaching the lungs, where replication occurs. Viral replication induces inflammation, leading to the activation of both the innate and acquired immune responses. An excessive immune response can result in the overproduction of large quantities of cytokines, including interferons (IFNs), interleukins (ILs), tumor necrosis factors (TNFs), transforming growth factors (TGFs), chemokines (CCLs), and C-X-C motif chemokines (CXCLs). This cytokine overproduction causes fluid leakage into lung cells, leading to hypoxia and severe lung damage, which can be fatal [<xref rid="B71-vaccines-12-01220" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-12-01220" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-12-01220" ref-type="bibr">73</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01220-g001.jpg"/></fig><fig position="float" id="vaccines-12-01220-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic representation of the virus life cycle and inhibition strategies employed by antiviral drugs for influenza virus and coronavirus [<xref rid="B95-vaccines-12-01220" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-12-01220" ref-type="bibr">96</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-12-01220-g002.jpg"/></fig><table-wrap position="float" id="vaccines-12-01220-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t001_Table 1</object-id><label>Table 1</label><caption><p>Comparison of influenza virus and coronavirus (SARS-CoV-2). &#8595; means decreas and &#8593; means increase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Features</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Influenza A Virus </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2 </th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vaccines-12-01220-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vaccines-12-01220-i002.jpg"/>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Year and pandemic name </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1918 (H1N1), 1957 (H2N2), 1968 (H3N2), 2009 (H1N1), and Flu pandemics </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019 and COVID-19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virus family</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Orthomyxoviridae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coronaviridae (genus &#946;-CoVs)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Structure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An enveloped, negative-sense, and single-stranded RNA virus; slightly ovoid or mostly round; diameter of 80&#8211;120 nm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An enveloped, positive-sense, and single-stranded RNA virus; spherical or round in shape; diameter of 60&#8211;140 nm</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genome size</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.5 kb</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.9 kb</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mode of transmission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Droplet, aerosol, direct contact, and fecal&#8211;oral route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Droplet, aerosol, direct contact, and fecal&#8211;oral route</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication sites</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Upper respiratory tract and, in severe cases, lower respiratory tract</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starts from the upper respiratory tract, infects the lower respiratory tract, and spreads to other organs (cardiovascular, intestinal, kidney, and nervous system)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incubation period</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#8211;7 days</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#8211;14 days (a maximum of 24 days)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Host receptor and entry </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminal glycosides of sialic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACE2 and TMPRSS2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cellular tropism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epithelial cells of Respiratory tract: Alveolar Epithelial cells and ciliated cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epithelial cells of the respiratory tract: alveolar epithelial cells, ciliated cells, basal cells of the olfactory epithelium, intestinal epithelial cells, renal parenchymal cells, and endothelial cells</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protein binding to host receptor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike (S) protein</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclear</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytoplasm</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fever, dry cough, sore throat, fatigue, and nasal congestion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High fever, dry cough, fatigue, ARDS, and anosmia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extrapulmonary complications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In rare cases, myocarditis and encephalitis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In most cases, anosmia, thrombosis, stroke, encephalitis, and diarrhea</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target for neutralizing antibodies</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA and NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD of the spike protein</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematological parameters</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymphopenia and CRP &#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type I interferon &#8595;, neutrophil counts &#8593;, and significant lymphopenia</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Variants of concern (VOCs) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1957 H2N2, 1968 H3N2, and 2009 H1N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alpha, Beta, Gamma, Delta, and Omicron</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mortality rate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05&#8211;0.1% (seasonal influenza)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~1&#8211;3.4% (higher in early wave)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine availability</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Annual seasonal vaccines (inactivated, live)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple vaccines (mRNA, vector-based, inactivated)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mutations/variants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigenic shift and drift</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Frequent mutations with variants of concern (e.g., Delta and Omicron)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Treatment options</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antivirals (e.g., oseltamivir and zanamivir)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antivirals (e.g., remdesivir, molnupiravir, and Paxlovid), mAbs</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Complications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia and secondary bacterial infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ damage</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">References</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-vaccines-12-01220" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01220" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-vaccines-12-01220" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01220" ref-type="bibr">29</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01220-t004" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t004_Table 4</object-id><label>Table 4</label><caption><p>Clinical trials on treatments for RV infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Identifier</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Classification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Function</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Camostat mesylate</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus A/B/SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04470544">NCT04470544</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TMPRSS2 serine protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blocking the virus activating host cell protease TMPRSS2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Baloxavir marboxil</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03684044">NCT03684044</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymerase acidic (PA) endonuclease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral replication</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Pimodivir</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02262715">NCT02262715</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02342249">NCT02342249</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I<break/>II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PB2 inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral replication</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Enisamium iodide</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04682444">NCT04682444</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04682873">NCT04682873</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III<break/>III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA polymerase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral replication</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DAS181</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza virus A/B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01173224">NCT01173224</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01651494">NCT01651494</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00527865">NCT00527865</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01037205">NCT01037205</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entry inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Removes sialic acid from epithelial cells, preventing viral entry</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Remdesivir</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04345419">NCT04345419</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04678739">NCT04678739</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit viral RNA replication by binding with viral RNA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Favipiravir</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04303299">NCT04303299</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04351295">NCT04351295</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04600999">NCT04600999</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04346628">NCT04346628</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04387760">NCT04387760</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04542694">NCT04542694</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03394209">NCT03394209</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>II/III<break/>III<break/>II<break/>II<break/>III<break/>II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral replication and genetic transversion</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ribavirin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01097395">NCT01097395</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01497366">NCT01497366</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04276688">NCT04276688</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04563208">NCT04563208</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV<break/>III<break/>II<break/>II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RdRp inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral RNA synthesis and immunomodulation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ivermectin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04403555">NCT04403555</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04381884">NCT04381884</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04646109">NCT04646109</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04591600">NCT04591600</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III<break/>II<break/>III<break/>I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral protein transport to nucleus</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ritonavir</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04303299">NCT04303299</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral Plpro protease activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Lopinavir</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04276688">NCT04276688</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04252885">NCT04252885</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II<break/>IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral protease inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibits viral 3CLpro activity</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Eculizumab</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04346797">NCT04346797</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents the activation of inflammation by inhibiting the C5 complement protein</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bevacizumab</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04275414">NCT04275414</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preventing acute lung injury in ARDS and suppression of pulmonary edema</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Meplazumab</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04275245">NCT04275245</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents viral entry and inflammation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Ramipril</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04366050">NCT04366050</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACE inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ras inhibitor to stop heart failure</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Azithromycin</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04332107">NCT04332107</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04381962">NCT04381962</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Regulates cytokine storm</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Chloroquine</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04420247">NCT04420247</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04353336">NCT04353336</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>II/III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Derivatives of quinine compounds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit virion formation and MAPK activation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Colchicine</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04322682">NCT04322682</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04472611">NCT04472611</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III<break/>III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-inflammatory drug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivates pro-inflammatory cytokines and migration of leukocytes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Baricitinib</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04421027">NCT04421027</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04373044">NCT04373044</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III<break/>II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JAK1/AAK1 inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suppresses inflammatory factors (IL-6 and IL7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Methylprednisolone</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04244591">NCT04244591</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04263402">NCT04263402</ext-link><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04273321">NCT04273321</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II/III/IV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Corticosteroid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lowers the viral lung damage</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>APN01-COVID-19</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SARS-CoV-2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04335136">NCT04335136</ext-link></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant human angiotensin-converting enzyme 2 (rhACE2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevents viral entry and viral replication</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01220-t005" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t005_Table 5</object-id><label>Table 5</label><caption><p>Summary of approved vaccines for the treatment of infections caused by influenza viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approved Country</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Influgen</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Lupin Laboratories Ltd., Mumbai, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">India</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluzone Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Sanofi Pasteur, Inc., Swiftwater, PA, USA</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>FluQuadri</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Sanofi-Aventis, Macquarie Park, Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Vaxigrip Tetra</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Sanofi-Aventis, Macquarie Park, Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluarix Tetra</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Glaxo-SmithKline Biologicals, Rixensart, Belgium</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Afluria Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Seqirus-Pty. Ltd., Parkville, Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluarix Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Glaxo-SmithKline Biologicals</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Fluad Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Seqirus, Inc., Holly Springs, NC, USA</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Agripal</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Chiron Panacea Vaccines Pvt. Ltd., New Delhi, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">India</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Influvac Tetra</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Mylan Health, Canonsburg, PA, USA</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Australia</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>FluLaval-Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">ID-Biomedical, Laval, QC, Canada</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>FlublokQuadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Sanofi Pasteur, Inc.</td><td align="center" valign="middle" rowspan="1" colspan="1">Recombinant influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Cadiflu-S Vaccine</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">CPL Biologicals Pvt Ltd., Ahmedabad, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">India</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>FluMist-Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Med-Immune, LLC., Gaithersburg, MD, USA</td><td align="center" valign="middle" rowspan="1" colspan="1">Live attenuated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Flucelvax-Quadrivalent</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Seqirus, Inc.</td><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">USA</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Nasovac S Vaccine</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum Institute of India Ltd., Pune, India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated influenza vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01220-t006" orientation="portrait"><object-id pub-id-type="pii">vaccines-12-01220-t006_Table 6</object-id><label>Table 6</label><caption><p>Summary of approved vaccines for the treatment of COVID-19.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Types of Vaccine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Produced by</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approval Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trials</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Countries Allowed Trials</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Approved Countries</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Covaxin</td><td align="center" valign="middle" rowspan="1" colspan="1">Bharat Biotech, Hyderabad, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td></tr><tr><td rowspan="11" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Physically or chemically inactivated viral vaccines </td><td align="center" valign="middle" rowspan="1" colspan="1">KoviVac</td><td align="center" valign="middle" rowspan="1" colspan="1">Chumakov Center, Moscow, Russia</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Turkovac</td><td align="center" valign="middle" rowspan="1" colspan="1">Health Institutes of Turkey, Ankara, Turkey</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FAKHRAVAC (MIVAC)</td><td align="center" valign="middle" rowspan="1" colspan="1">Organization of Defensive Innovation and Research, Tehran, Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">QazVac</td><td align="center" valign="middle" rowspan="1" colspan="1">Research Institute for Biological Safety Problems (RIBSP), Gvardeyskiy, Kazakhstan</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KCONVAC</td><td align="center" valign="middle" rowspan="1" colspan="1">Shenzhen Kangtai Biological Products Co., Shenzhen, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COVIran Barekat</td><td align="center" valign="middle" rowspan="1" colspan="1">Shifa Pharmed Industrial Co, Tehran, Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Covilo</td><td align="center" valign="middle" rowspan="1" colspan="1">Sinopharm, Beijing, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">93</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Inactivated (Vero Cells)</td><td align="center" valign="middle" rowspan="1" colspan="1">Sinopharm, Wuhan, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CoronaVac</td><td align="center" valign="middle" rowspan="1" colspan="1">Sinovac, Beijing, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SKYCovione</td><td align="center" valign="middle" rowspan="1" colspan="1">SK Bioscience Co. Ltd., Seongnam, South Korea</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLA2001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valneva, Saint-Herblain, France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein subunit vaccines</td><td align="center" valign="middle" rowspan="1" colspan="1">Zifivax</td><td align="center" valign="middle" rowspan="1" colspan="1">Anhui Zhifei Longcom, Hefei, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="16" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Use a protein fragment or viral spike proteins as the antigen to trigger an immune response</td><td align="center" valign="middle" rowspan="1" colspan="1">Noora vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Bagheiat-allah University of Medical Sciences, Tehran, Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Corbevax</td><td align="center" valign="middle" rowspan="1" colspan="1">Biological E Limited, Hyderabad, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Soberana 02</td><td align="center" valign="middle" rowspan="1" colspan="1">Instituto Finlay de Vacunas, Havana, Cuba</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Soberana Plus</td><td align="center" valign="middle" rowspan="1" colspan="1">Instituto Finlay de Vacunas</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">V-01</td><td align="center" valign="middle" rowspan="1" colspan="1">Livzon Mabpharm Inc., Zhuhai, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MVC-COV1901</td><td align="center" valign="middle" rowspan="1" colspan="1">Medigen, Taipei, Taiwan</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Recombinant SARS-CoV-2 Vaccine (CHO Cell)</td><td align="center" valign="middle" rowspan="1" colspan="1">National Vaccine and Serum Institute, Beijing, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nuvaxovid</td><td align="center" valign="middle" rowspan="1" colspan="1">Novavax, Gaithersburg, MD</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IndoVac</td><td align="center" valign="middle" rowspan="1" colspan="1">PT Bio Farma, Bandung, Indonesia</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Razi Cov Pars</td><td align="center" valign="middle" rowspan="1" colspan="1">Razi Vaccine and Serum Research Institute, Karaj, Iran</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VidPrevtyn Beta</td><td align="center" valign="middle" rowspan="1" colspan="1">Sanofi/GSK, Lyon, France/Brentford, UK</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">30</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">COVOVAX</td><td align="center" valign="middle" rowspan="1" colspan="1">Serum Institute of India, Pune, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TAK-019 (Novavax formulation)</td><td align="center" valign="middle" rowspan="1" colspan="1">Takeda, Tokyo, Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SpikoGen</td><td align="center" valign="middle" rowspan="1" colspan="1">Vaxine/CinnaGen Co., Adelaide, Australia</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aurora-CoV</td><td align="center" valign="middle" rowspan="1" colspan="1">Vector State Research Center of Virology and Biotechnology, Koltsovo, Russia</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EpiVacCorona</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vector State Research Center of Virology and Biotechnology</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-replicating viral vector vaccines</td><td align="center" valign="middle" rowspan="1" colspan="1">iNCOVACC</td><td align="center" valign="middle" rowspan="1" colspan="1">Bharat Biotech</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Bioengineered viral vectors that are unable to express and clone antigens originating from the targeted virus</td><td align="center" valign="middle" rowspan="1" colspan="1">Convidecia</td><td align="center" valign="middle" rowspan="1" colspan="1">CanSino, Tianjin, China</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Convidecia Air</td><td align="center" valign="middle" rowspan="1" colspan="1">CanSino</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abdala</td><td align="center" valign="middle" rowspan="1" colspan="1">Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gam-COVID-Vac</td><td align="center" valign="middle" rowspan="1" colspan="1">Gamaleya, Moscow, Russia </td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sputnik Light</td><td align="center" valign="middle" rowspan="1" colspan="1">Gamaleya</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sputnik V</td><td align="center" valign="middle" rowspan="1" colspan="1">Gamaleya</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">74</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jcovden</td><td align="center" valign="middle" rowspan="1" colspan="1">Janssen (Johnson &amp; Johnson), New Brunswick, NJ</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">113</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vaxzevria</td><td align="center" valign="middle" rowspan="1" colspan="1">Oxford/AstraZeneca, Oxford, UK</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">73</td><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">149</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Covishield</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum Institute of India</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">49</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA vaccines</td><td align="center" valign="middle" rowspan="1" colspan="1">GEMCOVAC-19</td><td align="center" valign="middle" rowspan="1" colspan="1">Gennova Biopharmaceuticals Limited, Pune, India</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vaccines based on mRNA that are combined with injectable nanoparticles to efficiently transfer the mRNA into target cells and induce adaptive immunity </td><td align="center" valign="middle" rowspan="1" colspan="1">Spikevax</td><td align="center" valign="middle" rowspan="1" colspan="1">Moderna, Cambridge, MA, USA</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">70</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spikevax Bivalent Original/Omicron BA.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Moderna</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">38</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spikevax Bivalent Original/Omicron BA.4/BA.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Moderna</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comirnaty</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer/BioNTech, New York, NY, USA/Mainz, Germany</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">149</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comirnaty Bivalent Original/Omicron BA.1</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer/BioNTech</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">35</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Comirnaty Bivalent Original/Omicron BA.4/BA.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Pfizer/BioNTech</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">33</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TAK-919 (Moderna formulation)</td><td align="center" valign="middle" rowspan="1" colspan="1">Takeda</td><td align="center" valign="middle" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AWcorna</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Walvax, Kunming, China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Approved</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccines</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ZyCoV-D</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Zydus Cadila, Ahmedabad, India</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Approved</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA vaccines comprise of a plasmid that has been genetically modified to encode the antigen unique to the disease and a vector that transports the plasmid into the host cell.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VLP vaccines</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Covifenz</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Medicago, Quebec City, QC, Canada</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Approved</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spontaneously assembled from several structural proteins of the virus to stimulate the immune system </td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>